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1.1. The burden of musculoskeletal disorders 
Musculoskeletal disorders affect hundreds of millions of people around the world and are 
related to important limitations in functioning as defined in the “International Classification 
of Functioning, Disability and Health” (ICF) [1, 2]. In the ICF functioning is no longer seen 
as the consequence of a disease but in relation to a health condition, as well as to personal 
and environmental factors. Due to the significant limitations in functioning, the economic 
burden related to musculoskeletal chronic diseases is substantial and the impact of these 
disorders on individuals and on society is expected to increase dramatically [1, 3]. In a 
recent health survey targeting the burden of diseases across chronic conditions, the impact 
of disorders like osteoarthritis, low back pain, fibromyalgia and osteoporosis was considered 
comparable to the impact of major diseases such as cardiac conditions [4]. In 
musculoskeletal disorders indirect costs are usually predominant and greater than direct 
costs due to productivity loss costs [1]. However, for lifelong musculoskeletal disorders like 
osteoarthritis, osteoporosis or low back pain, which affect a considerable number of older 
and already retired persons, as well as for patient populations with high health resource 
consumption like fibromyalgia patients, the use and more specifically the high use of health 
care services and the resulting direct costs are of concern for public health policy makers 
[5]. According to estimates of the German Federal Statistic Office direct costs related to 
musculoskeletal chronic diseases were estimated to amount to €25.2 billion in 2002 [6]. 
Osteoarthritis can be characterized by loss of joint cartilage leading to pain and loss of 
function mainly in hips and knees, is strongly associated with aging and the course of the 
disease is often progressive [1]. Because it is not a simple disease entity, it is difficult to 
estimate incidence and prevalence [7] but high prevalence is always attested wherever such 
statistics are available [8]. It is supposed that worldwide about 10% of persons over the age 
  
 6 
60 have clinical problems related to osteoarthritis [7]. In Australia a prevalence of 2.65% for 
males and 4.17% for females was estimated [7]. The financial burden specifically of 
posttraumatic osteoarthritis were estimated to be $3.06 billion annually in the USA [9]. 
Total annual disease costs were estimated to amount to $5700 in Canada [10]. Average 
total annual osteoarthritis-attributable costs in Spain were €1502 per patient and direct 
costs accounted for 86% of the total cost [11]. Excluding joint replacement, direct costs 
related to osteoarthritis in Hong Kong ranged from Hong Kong dollar $11,690 to $40,180 
per person per year [12]. In general, the economic burden of arthritis ranges between 1% 
and 2.5% of the gross national product of western nations [8].  
Osteoporosis is characterized by low bone mass and deterioration of bone tissue with 
consequent increase in susceptibility to fractures and is strongly associated with aging as 
well as with being female [1]. The prevalence of osteoporosis is estimated to be 54% in 
postmenopausal women in the USA, 23% in women aged >50 years in the United Kingdom 
and even 70% among American women by the age of 80 years [1, 13]. In the year 2003 7.8 
million Germans (6.5 women) suffered from osteoporosis, equalling a prevalence rate of 39% 
in women and 9.7% in men [14]. Worldwide it is estimated that over 200 million people 
suffer from osteoporosis [15]. Fractures associated with osteoporosis are highly related to 
pain, mortality and loss of mobility and consequently a considerable burden to health care 
systems [13]. More than 2 million incident fractures at a cost of $17 billion were predicted 
in the USA for the year 2005 and total estimated costs including prevalent fractures 
exceeded 19$ billions [16]. In Germany 108.341 osteoporosis-attributable hip fractures 
were associated to direct costs amounting to 2736 millions of Euros [17]. In 2003 total 
direct costs attributable to osteoporosis in Germany amounted to €5.4 billion [14].  
Back pain can be defined as acute, sub-acute or chronic if it lasts less than six weeks, between 
six weeks and three months or more than three months, respectively. About 90% of cases are 
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classified as non-specific, i.e. without suspected pathological cause [1]. It is a leading cause 
of disability and its prevalence and incidence are roughly the same worldwide [18]. Lifetime 
prevalence varies between 58% and 84% and the point prevalence between 4% and 33% [1]. 
The economic burden of back pain is huge wherever it is estimated and a small percentage of 
patients accounts for a large fraction of costs [19]. However, the methodology used to 
estimate costs related to back pain markedly differ between studies and leads to a 
challenging variability of reported direct costs [20]. In a recent review targeting the cost-
of-illness of back pain, annual direct costs ranged from about €187 Million in Belgium to 
over $90 Billion in the USA [20]. 
Fibromyalgia is characterized by widespread musculoskeletal pain, fatigue and tenderness of 
unknown aetiology and up to 85% of the patients with fibromyalgia are women of 
childbearing age or older [21, 22]. The prevalence of fibromyalgia is estimated to range 
from 2% to 12% in the general population [23] and increases with age [24]. About 15% of 
patients seen by rheumatologists and 6% of patients in other practice settings are diagnosed 
as having fibromyalgia [24]. The economic burden of fibromyalgia is substantial since 
patients show high levels of health resource utilization and comorbidities [21, 25, 26]. 
Recently estimated total annual healthcare costs per patient were $9573 in the USA [22] 




1.2. Targeting and evaluating the economic burden related to musculoskeletal 
disorders 
Musculoskeletal disorders like osteoarthritis, osteoporosis, back pain and fibromyalgia have 
in common a chronic and often debilitating course of disease. Patients’ functioning is 
therefore a central aspect of these musculoskeletal disorders and both restoring and 
optimizing functioning the main goal in healthcare [27, 28]. From the public health 
perspective, rehabilitation is the strategy in health care whose goal is optimal functioning 
[28]. Using the terminology of the ICF, the main aim of rehabilitation is “to enable people 
with health conditions experiencing or likely to experience disability to achieve optimal functioning in 
interaction with the environment” [28].  
Rehabilitation of patients suffering from osteoarthritis, osteoporosis, back pain or 
fibromyalgia is therefore essential and achieves its goal “by applying and integrating approaches 
to optimize a person’s capacity, approaches which build on and strengthen the resources of the person, 
which provide a facilitating environment, and which develop performance in the interaction with the 
environment” [28]. Due to the increasing economic burden related to osteoarthritis, 
osteoporosis, back pain, fibromyalgia and the limitability of health resources, an additional 
task of rehabilitative interventions is the reduction of excessive direct costs related to 
inappropriate disease management [29]. 
The evaluation of the effectiveness of rehabilitation programs is essential to determine 
whether a program achieves its goals. Since reducing excessive direct costs is also a task of 
rehabilitation, it is no more sufficient to design research studies simply addressing the 
question whether new interventions or services are effective [30]. Rehabilitation programs 
have to be examined not only with regard to effectiveness but also to cost-effectiveness, 
which means with regard to the relation between resources used and resulting outcome. The 
inclusion of alongside economic evaluations, targeting mostly a cost-effectiveness analysis of 
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such rehabilitation programs, is therefore fundamental and has often become a prerequisite 
to get research projects granted in the field of rehabilitation in Germany.  
However, clinical researchers are often overstretched by the need to perform an economic 
evaluation. Firstly, obtaining sound health resource use data is a challenge. On the one side, 
the access to health insurance data is restricted and its evaluation very complex [31, 32]. On 
the other side, there are almost no self-administered questionnaires available for routine 
health care resource use data collection. Secondly, guidelines on economic evaluations are 
quite complex in their terminology and very comprehensive sets of cost categories are 
proposed to be included in economic evaluations [33, 34]. These comprehensive sets are 
very important to economists targeting cost-of-illness studies but become a barrier to 
clinical researchers targeting pre-post or between-group comparisons alongside their 
clinical studies. Thirdly, if a new intervention is expected to be cost-effective, it is important 
to know what to target in rehabilitation in order to achieve cost-effectiveness. It is traceable 
that rehabilitation programs aiming solely at clinical outcomes cannot be expected to reduce 
excessive direct costs to the same degree as interventions that directly aim at outcomes that 
have an immediate impact on health care resource consumption. The cost-effectiveness goal 
has also to be considered in the development phase of the rehabilitation programs, i.e. what 
to target in order to avoid the incurrence of excessive and avoidable costs must be a clearly 
defined priority.  
Due to the importance of alongside economic evaluations of clinical studies among patients 
with musculoskeletal disorders, it is essential to establish the parameters necessary to 
perform sound economic evaluations routinely. In order to establish those parameters and 
facilitate economic evaluations alongside studies targeting the effectiveness of rehabilitation 
programs, it is essential to firstly define methods of measuring health care resource 
utilization, i.e. to define how to measure. Secondly, it is crucial to identify which health 
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resource utilization domains are relevant and sufficient to estimate reliable figures of direct 
costs in order to perform pre-post or between-group cost analyses, i.e. to define what to 
measure. Thirdly, when designing rehabilitation programs for musculoskeletal patients 
targeting also the reduction of excessive and avoidable costs related to medical treatment, it 
is important to consider which factors are determining such costs in the development phase 
of new interventions, i.e. to define what to target.  
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1.3. Measurement of health care resource utilization 
A crucial and challenging task in an economical evaluation is the sound measurement of 
health care resource utilization. Most relevant cost data can be obtained from computerized 
medical and health insurance records, which can be expected to provide accurate and 
detailed information on health care resource use. However, the access to this data is 
restricted, the analysis complex and very detailed extra written informed consents are 
needed due to legal data protection [31, 32].  
Consequently, researchers in the field of health economics frequently use data obtained from 
self-administered questionnaires, which are almost always feasible but potentially vulnerable 
to recall bias. Disparities between information from self-reported questionnaires and from 
provider’s records have been indeed often described and recall bias seem to depend on the 
duration of the recall period and on the saliency of the health service [35]. While a tendency 
towards under reporting could be identified for physician visits [36, 37], emergency room 
and physiotherapists visits tended to be slightly over reported [36, 38].  
Despite the vulnerability of self-reported information to recall bias, some studies show that 
patient reported data can also be accurate for specific categories. No significant differences 
between patients' and providers' reports with respect to hospital days and outpatient visits 
were found in two studies [37, 39]. Further studies aiming for precision and accuracy of 
self-administered questionnaire data on sick leave showed that patients report their 
productivity losses adequately provided that recall periods are not longer than 3 months 
[40, 41].  
Owing to the fact that measures of resource utilization are often applied on an ad hoc basis 
[42], many efforts have been made in the past years to improve the quality and reliability of 
self-administered questionnaires [31, 43]. In a comprehensive review targeting cost 
domains used in economic evaluations of rheumatic diseases, a preliminary scheme to 
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categorize cost assessment was proposed [33]. Moreover, a generalized matrix of applicable 
resource utilization domains for musculoskeletal conditions has been developed [34].  
However, few standardised self-completion resource use questionnaires have been developed 
and validated in the past decade. An instrument for use in economic studies of early 
inflammatory polyarthritis was developed, pilot-tested and validated in the UK [44]. 
Similarly, a Canadian group developed and tested the feasibility and validity of a 
questionnaire to assess health care utilization after occupational low-back pain (LBP) [45]. 
In addition, the health economic questionnaire for rheumatoid arthritis (HEQ-RA) was 
developed and validated in Germany [41, 46].  
Due to this scarcity of standardised and validated instruments, many studies develop their 
own questionnaires to assess health care resource utilization but rarely describe instrument 
characteristics. However, to enhance the process towards standardized and validated self-




1.4. Identification of relevant health care use domains 
Economic evaluations in chronic musculoskeletal conditions show a challenging 
inconsistency in reported direct medical costs. Recent reviews as well as a survey targeting 
economic evaluations in the indications low back pain, osteoarthritis and rheumatoid 
arthritis pointed out that the wide rage of direct cost estimates within a medical condition 
restricts the comparability of studies significantly [20, 47, 48].  
Variability in the dimension of direct medical costs can be explained by the design of 
economic evaluations, i.e., the choice of different perspectives, diverse health care systems 
and different data sources, among others. However, one of the key factors leading to hardly 
comparable direct medical costs is the substantial variability of health resources categories 
used to estimate costs [20, 47, 49].  
Owing to the lack of standardization, matrixes of applicable cost categories have been 
developed in the past years for musculoskeletal conditions [33, 34]. Authors suggest that at 
least visits to physician, outpatient surgery, non physician service utilization, drug expenses, 
diagnostic/therapeutic procedures and tests, emergency room visits, aids and devices, 
inpatient acute hospital facilities with or without surgery and nursing homes and 
rehabilitation should be included in any analysis [34]. 
However, the selection of cost categories during the development of an economic evaluation 
depends strongly on the purpose of the study. Comprehensive core sets of cost categories are 
fundamental to perform cost-of-illness studies targeting the economic burden of a disease. In 
contrast, in economic evaluations alongside cohort studies, which are targeting either pre-
post or between-group cost comparisons, brief core sets of most relevant cost domains 
including as many categories as necessary and as few as possible are recommended [36, 50]. 
In fact, some recent economic evaluations have included only four cost categories [physician 
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visits, medication, inpatient treatment, non physicians service use] to estimate direct 
medical costs [51-54]. 
Thus, it is crucial to identify which resource utilization domains are relevant and sufficient 
to estimate reliable figures of direct medical costs in order to perform pre-post or between-
group cost analyses. The decision on which categories to use can be elicited by ranking the 
percentage of direct medical costs represented by each cost category. In doing so, it is 
important to decide on a cut-off. Categories have been considered of minor importance if 
they contribute to less than 1% of the total direct costs [53, 55]. However, any cut off is 
somewhat arbitrary and will depend on the purposes of the study. 
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1.5. Determinants of direct medical costs 
An in-depth understanding of the determinants of the economic burden related to the 
medical treatment of musculoskeletal diseases is the prerequisite to develop tailored cost-
saving rehabilitative interventions.  
During the last decade, many studies have attempted to identify determinants of direct costs 
among patients with chronic musculoskeletal conditions. Functional status measured by 
health related quality of life (HRQoL) instruments was a relevant predictor across 
musculoskeletal conditions. In RA the Health Assessment Questionnaire (HAQ) was 
consistently an important predictor of direct costs [5, 56-59]. In addition to the HAQ 
comorbidity, sociodemographic characteristics [60] and the mental health scale of the 
Medical Outcomes Study Short Form-36 (SF-36) [61] were identified as predictors. The 
HAQ was also the most pronounced predictor of direct costs beyond the median among 
patients with a disease duration of more than two years [62]. In fibromyalgia the number of 
comorbidities and the fibromyalgia disability, measured with the Fibromyalgia Impact 
Questionnaire (FIQ), were significant determinants of direct costs [59, 63]. Additionally, 
one study among fibromyalgia patients identified not only comorbidity and disability but 
also health status, disease severity, perceived self-efficacy, depression and social support as 
predictors of direct costs beyond the median [64]. In osteoarthritis (OA) the Western 
Ontario Osteoarthritis Index (WOMAC) stiffness, duration of disease and gender were 
determinants of out-of-pocket expenditures [65], while poorer scores in the dimensions of 
the SF-36 were a major determinant of direct costs [66]. A study targeting specifically the 
impact of HRQoL instruments on future health care resource use in patients with RA and 
osteoarthritis also concluded that SF-36, HAQ as well as the WOMAC were all strong 
predictors of future health care resource consumption [5]. 
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However, there is a lack of studies aiming to identify the determinants of direct costs among 
patients with osteoporosis or back pain and few studies specifically targeted determinants of 
high direct costs (beyond the median) among patients with chronic musculoskeletal 
disorders [62, 64]. Yet, the understanding of determinants of direct medical costs across 
medical conditions is of major importance regarding the development and implementation of 
efficient rehabilitative interventions. Efficient interventions should aim not only for 
improvements in functioning but also for a reduction of high and avoidable direct medical 
costs. Since such interventions can only be developed if the target population is clearly 
defined, the identification of subjects at risk of incurring high and potentially avoidable 
direct medical costs is essential. 
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2. Research Objectives 
The overall objective of this doctoral thesis is to address some of the conditions necessary to 
routinely perform alongside economic evaluations of rehabilitation programs.  
The specific aims are to 1) present a standardized instrument to collect data about health 
care resource use, 2) identify major cost categories of direct medical costs to be used in 
comparative economic evaluations of subjects with musculoskeletal diseases and 3) identify 
determinants of direct medical costs among subjects with musculoskeletal diseases.  
This doctoral thesis is therefore divided into three parts. In the first part a standardized 
instrument to collect health care resource use in the context of rehabilitation is described 
and lessons learned are discussed. In the second part major direct medical costs categories 
among patients with musculoskeletal conditions undergoing outpatient rehabilitation are 
identified, and in the third part determinants of direct medical, as well as of direct medical 
costs above the median incurred by chronic musculoskeletal patients, are examined. Each of 
these parts contains a specific discussion section referring to their specific results. 
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3. “Development of an instrument to collect health care 
resource use data in the context of rehabilitation” 
3.1. Objective 
The general objective of this part of the doctoral thesis is to describe an instrument to 
collect health resource utilization data and to discuss lessons learned. The instrument to 
collect health care resource use data described here could not be validated so far. However, 
much could be learned from the application of the standardized questionnaire. These 
insights can contribute to other groups embarking in similar studies and can support the 
realization of a standardized and validated self-administered general questionnaire suitable 
for the collection of relevant cost data in rehabilitation interventions. 
3.2. Methods 
The questionnaire to collect health resource utilization data was developed for the economic 
evaluations of five rehabilitation studies funded by the German Federal Ministry of 
Education and Research (BMBF). The development was based on the methodological 
standards of health costs data assessment proposed by the “Working Group Methods in 
Health Economic Evaluation” (MEA) [67, 68]. 
Considering the health condition of study patients, specific questions of each associated 
study and recommendations of the MEA, it was decided which health resource use 
components should be part of the questionnaire and which recall period would be adequate. 
All questions in the health resource use assessment questionnaire referred to the underlying 
disease targeted in the rehabilitation or prevention program. All questions had a first 
dichotomous level of aggregation (Yes/No) and included a table requesting further detailed 
information about health resource use.  
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Health resource utilization data was collected to estimate direct medical, direct non medical 
and indirect costs. Estimated figures were used either to compare costs before and after 
interventions or to perform incremental cost-effectiveness analyses. In order to estimate 
direct medical cost categories data was collected about outpatient medical care, day care 
treatment, inpatient treatment, outpatient hospital treatment, medication, non physician 
service utilization, emergency service and aids and devices. In order to estimate direct non 
medical cost categories data about sport, relative’s care giving, participation in self-help 
groups (leisure time loss) and transportation costs was collected. The question targeting 
transportation costs was a sub item of the items outpatient medical care, day care treatment, 
outpatient hospital treatment and non physician service utilization. Only patients who used 
at least one of the services described above were asked to give further information on 
transportation costs. In order to estimate indirect costs data about days of sick leave of 
gainfully employed persons and early retirement was requested. 
In order to validate the instrument, a data evaluation of records of a compulsory insurance 
fund was planned for two studies. A comparison of information obtained with the 
questionnaire regarding day care treatment, inpatient treatment, aids and devices, non 




The standardized self-administered retrospective health resource use assessment 
questionnaire was answered by a total of 1042 subjects with one of the following 
indications: osteoarthritis, osteoporosis, back pain, cancer, fibromyalgia or brain/cranial 
traumata. 
Table 1 Summary of associated studies. 
 
Study S1 S2 S3 S4 S5 
Main goal 
Group psychotherapy 
of dysfunctional fear 
of progression in 
patients with chronic 
arthritis and cancer 






Evaluation of a 
comprehensive skills-
oriented cognitive 
therapy in the 
neurological 
rehabilitation 
Evaluation of a 
multidisciplinary 
prevention program 
for nurses with low 
back pain 













Back pain (143) 
Traumatic Brain 
Injury (115) 
Back pain (169) Fibromyalgie (72) 
Patient 
recruiting  
October 2002 to 
December 2003 
1. Quarter 2003 to    
1. Quarter 2005 
January 2003 to    
June 2006 
July 2003 to   
February 2005 




RCT Longitudinal study RCT RCT 
Prospective cohort 
study 
Context Rehabilitation Rehabilitation Rehabilitation Prevention Rehabilitation 
Data 
assessment2 
12 months pre 
3 months post 
12 months post 
12 months pre 
6 months post 
6 months post 
12 months post 
12 months pre 
3 months post 
12 months post 
6 months pre 
6 months post 
Cost 
Categories 
Direct medical costs 
Direct non medical 
costs 
Indirect costs 
Direct medical costs 
Direct non medical 
costs 
Indirect costs 
Direct medical costs 
Direct non medical 
costs 
Indirect costs 
Direct medical costs 
Direct non medical 
costs 
Indirect costs 
Direct medical costs 




The five associated studies were: “Group psychotherapy of dysfunctional fear of progression in 
patients with chronic arthritis and cancer” (S1) [69, 70]; “Feasibility of the Willingness-to-pay 
methodology for expected and perceived health effects” (S2) [71]; “Evaluation of a comprehensive 
skills-oriented cognitive therapy in the neurological rehabilitation” (S3) [data not published.]; 
                                                 
1
 Number of patients who answered the questionnaire 
2
 Pre or post intervention 
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“Evaluation of a multidisciplinary prevention program for nurses with low back pain” (S4) [72]; 
and “Evaluation of a multimodal therapy program for fibromyalgia patients” (S5) [data not 
published]. Study design of each associated study is described in detail in Table 1. The 
versions of the questionnaire adapted for each study are presented in the Appendix except 
for the versions of study S1. Study S1 integrated the questions targeting ressource use in 
their own case record form. The health resource use categories selected to be collected in 
each study are presented in Table 2.  
Table 2 Cost categories assessed in the five associated studies. An “X” means that the category was included in 
the questionnaire. 
 


































































































































































































































































































Outpatient medical care X X X X X 
Day care treatment X X X - X 
Inpatient treatment X X X X X 
Outpatient hospital treatment X X - - X 
Rehabilitation - - - X - 
Medication X X X X X 
Non physician service utilization X X X X X 
Emergency service - X X X X 
Aids and Devices X X X X X 
Sport - - - X - 
Adaptations/rebuilding at home - - X - - 
Relatives care giving X X - - - 
Occupational Training X X X X X 
Self help groups X X X - X 
Transportation costs - X X - X 
Retirement X X X - X 
Sick leave X X X X X 
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The cost categories outpatient medical treatment, inpatient treatment, medication, non 
physician service utilization, devices and aids, occupational training and sick leave days were 
collected in all studies. Cost components are described in Table 3.  
Direct medical costs. In the question about outpatient medical care data concerning 
general practitioner and specialists visits was requested. Data requested about non physician 
outpatient service always included information about physiotherapy, massage, occupational 
therapy, psychotherapy and alternative practitioner therapy. The more detailed further 
information was requested on these items, the higher the percentage of incomplete answered 
questions at baseline and in the follow up. Comprehension problems were identified in the 
question about outpatient treatment in a hospital. Patients often could not differentiate 
between day care treatment in a hospital and outpatient treatment in a hospital. In the initial 
version of the questionnaire many double answers regarding medication were identified if 
information about both prescribed and out-of-pocket medication were separately requested 
in two questions. Information about medication was therefore summarized in a single 
question in the following versions. 
Direct non medical costs. Data collected about sport activities, relative’s care giving and 
participation in self-help groups aimed to calculate the amount of leisure time lost because of 
the disease. Considering the monetary valuation there was no need of further information 
beyond the number of hours spent with the activities described above. The item 
transportation cost was very poorly answered and so could not be included in the calculation 
of the direct non medical costs.  
Indirect costs. Data about early retirement and days of sick leave was collected to estimate 
indirect costs. In order to avoid answers from retired or unemployed patients, only gainfully 
employed persons were requested to give information about sick leave and early retirement. 
In Germany, employed subjects do not need to present a sick certificate in the first three 
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days of absenteeism due to sickness. We asked therefore for sick leave days from the very 
first day with and without medical certificate. Information about temporal limited 
absenteeism due to visits to a physician, for instance, was also requested but poorly 
answered, so that it could not be considered in the calculation of indirect costs. 




Subcategories Physical units Further information Recall period 
Outpatient 
medical care 
 general practitioner 
 Specialists (as 
orthopaedists, 
internist, neurologist 
and etc.)  




 Number of visits   last 4 weeks  






 Day care 
 Rehabilitation 
 Length of 
stay/treatment 
 Hospital specification 
 Clinic specification 
 Diagnosis 
 Total researched 
period, not asked at 
the 3 months follow 
up 
 Outpatient: last 4 
weeks 
 
Medication  Prescribed  
 Out of pocket  
 Piles or Infusions a 
day 
 Additional payment 
 Drug name  Last 4 weeks 







 Occupational therapy 
 Psychotherapy  
 Alternative 
Practitioner 
 Other Interventions 
 
 Number of 
interventions 
 Specification of the 
intervention 
 Last 4 Weeks 




 Emergency room 
 Doctor on call 
 Ambulance without 
physician 
 Ambulance with 
physician 
 
 Number of services   Total researched 
period, not asked at 




 None  Price 




 Total researched 
period, not asked at 








Subcategories Physical units Further information Recall period 
Sport  Gymnastic course 
 Gymnastic at home 
 Swimming 
 Fitness centre 
 PMR 
 Autogenic training 
 Another sport 
 
 Number of hours per 
week 
 Number of months 
  Total researched 
period, not asked at 
the 3 months follow up 
Home 
adaptations 
or rebuilding  
 




 Cost carrier 




 Home nursing 
 Escort for medical 
appointments 
 Collection of 
medication 
 Help in housekeeping  
 Other form of help 
 
 Number of hours per 
week 





 Occupational training 
 On-the-job training 
 Other training 
 
 Number of weeks  Cost carrier  Total researched 
period, not asked at 
the 3 month follow up 
Participation 





 None  Number of months 
 Number of hours per 
month 
  Total researched 
period, not asked at 
the 3 month follow up 
 
     
Transport- 
ation costs 
 None  total costs  Transport mean 
specification 
 due to physician visits, 
no physician 
interventions, 
outpatient and day 




 Receiving a pension 
 Applied for a pension 
 Granted a pension 
 
 Retirement date  Pension specification  Total researched 
period, not asked at 
the 3 months follow up 
Sick leave  Sick leave days with 
medical certificate 
 Sick leave days 
without medical 
certificate 
 Temporal limited 
absenteeism due to 
visits to i.e. physician 
 How many days 
 How many hours 
(limited absenteeism) 






The general objective of this paper was to describe the development of an instrument to 
collect self-reported health resource utilization, its application in five rehabilitation studies 
and to discuss lessons learned. The questionnaire was answered satisfactorily and provided 
enough information to calculated direct medical, direct non medical and indirect costs. 
The vulnerability of self-reported information to recall bias is a major issue of patient-
reported data. As no objective data was available, assumptions about the impact of our recall 
periods on cost figures can not be made. It has been shown that the tendency to report less 
accurate service utilization appears to be exacerbated when the recall period is extended 
[35]. Since short recall periods of four weeks were used to assess information on medication, 
physician visits, relatives care giving and non physician service utilization, the probability of 
recall bias regarding these categories is low. The longer recall period of six months or more 
used to assess inpatient treatment has been considered adequate in the literature [37, 39]. 
However, the recall period of six months or more used for emergency services, aids and 
devices, sport, rebuilding, participation in self-help groups and sick leave might have been 
problematic. Especially the accuracy of sick leave information was shown to work better for 
short periods of time up to 3 months [40, 41]. 
The questionnaire used to collect health resource utilization was adapted considering the 
needs of each associated study. However, no advantage in adapting the original 
questionnaire could be observed. It could be learned that the level of detail regarding 
outpatient medical care, non physician service utilization, sport and relatives care giving was 
too comprehensive and became very sensitive to missing values with no advantages for the 
economic evaluation. Indeed, the inclusion of highly aggregated items rather than very 
detailed questions has already been suggested [36, 46]. The decision on which health 
resource use components should be part of the questionnaire was based on the underlying 
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health condition of study patients, specific questions of the associated studies and 
recommendations of the MEA. However, the aims of the alongside economic evaluations 
were either the pre-post or between-group comparison of costs before and after 
interventions or a cost-effectiveness analysis. The use of a core set of major cost categories 
would have been therefore more appropriate in order to guarantee the comparability of 
results across studies. Indeed, economic evaluations in rehabilitation frequently include only 
major cost categories as medication, physician visits, non physician services use and 
inpatient treatment to estimate direct medical costs [51-54]. 
The development of a general and brief instrument to collect health resource use including 
only major categories is crucial to enhance the process towards comparable alongside 
economic evaluations in the field of rehabilitation. Due to the scarcity of standardized 
instruments to collect health resource use, the development of such an instrument would 
guarantee standardization and comparability between studies and across indications. Indeed, 
the use of pre-defined major cost categories, which should be covered by each socio-
economic evaluation, has already been suggested [73]. 
A limitation of the questionnaire is that it could not be validated. This happened because of 
reservations regarding the need of an extra informed consent and because one project did 
not recruit as many patients as required from the health insurance fund to deliver 
information. Indeed, similar problems with the validation of cost data are quite usual and 
have already been described [38, 45]. 
The development of a standardized general brief questionnaire to collect health resource use 
with predetermined cost categories is important to enhance the process towards 
standardization of economic evaluations. However, the validation of such an instrument is 
essential and needs further research. The development of additional “disease-related 
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modules” that could be added to the general questionnaire if disease-specific information is 
needed is also recommendable. 
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4. “Identification of major direct medical cost categories among 
patients with musculoskeletal conditions undergoing 
outpatient rehabilitation” 
4.1. Objective 
The general objective of this part of the doctoral thesis is to identify major cost categories of 
direct medical costs among patients with musculoskeletal conditions undergoing a 
rehabilitation program. The specific aims are 1) to identify major cost categories in our 
population and 2) to report means and 95% confidence intervals calculated with or without 
minor important categories. 
4.2. Methods 
The present evaluation was performed alongside two cohort studies and included 410 
patients with indications of fibromyalgia, osteoarthritis, osteoporosis or back pain 
undergoing outpatient rehabilitation at the Department of Physical Medicine and 
Rehabilitation of the University Hospital Munich. Further inclusion criteria were: patients 
were at least 18 years old and had agreed to participate in the study by written, informed 
consent. General exclusion criterion was poor command of the German language. 
Fibromyalgia subjects were also excluded in cases of severe concomitant physical or mental 
illnesses. Fibromyalgia patients took part in a cohort study targeting the effect of a 
psychological group intervention on patient’s locus of control (data not published). 
Osteoarthritis, osteoporosis and back pain subjects took part in a prospective cohort study 
targeting the feasibility of the willingness-to-pay methodology for expected and perceived 
health effects [71]. 
Resource consumption was assessed with the self-report retrospective questionnaire to 
collect health resource use reported in the first part of this doctoral thesis. Patients 
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answered the questionnaire at baseline and six months after the intervention. The cost 
categories considered were outpatient physician services, non physician health services, 
medication, inpatient treatment, outpatient treatment in a hospital, emergency services, aids 
and devices, participation in self-help groups, nursing care from relatives and sick leave 
days. Outpatient treatment in a hospital was very poorly answered and therefore not 
included in the calculation of the direct medical costs. 
This work was performed from the societal perspective. Resource use volumes were 
combined with unit costs to obtain a net cost per patient over the entire period and 
extrapolated to obtain annual figures. Medication was valuated on the basis of prices of the 
online German drugs index book [74]. Devices and aids were valuated with prices charged 
by a Bavarian health insurance fund [75]. All other index costs were proposed by the 
Working Group Methods in Health Economic Evaluation (AG MEA) [43, 67, 68]. These 
index costs were extrapolated for 2004 using a factor of 0.025 for the first year and 0.020 for 
the following years. All costs were calculated in Euros for the year 2004. 
We discriminated minor from major cost categories ranking the percentage of direct medical 
costs represented by each cost category and using a cut off of 5%, i.e., cost categories 
contributing to less than 5% of the direct medical costs at baseline were considered to be of 
minor importance. Mean [95% CI] estimates of direct medical costs calculated either with 
all available cost categories or solely with major resource utilization domains are reported.  
In order to be informative for health care policy decisions, cost analyses have to report 
arithmetic mean costs since only these will enable the calculation of total treatment costs 
[76]. Standard non-parametric methods as well as the report of medians are therefore not 
appropriate for economic evaluations. However, as cost data is usually highly skewed 
distributed, original arithmetic means tend to be biased so that bootstrap techniques are 
recommended to estimate valid arithmetic means. Hence, we used non parametric bootstrap 
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techniques with 1000 replications in order to estimate means and 95% confidence intervals 
[95% CI]. Statistical calculations were performed using SPSS version 14.0. 
4.3. Results 
Socio-demographic characteristics of our sample are described in Table 4. Direct medical 
costs were available for 301 (73.4%) subjects at baseline and for 291 (71%) subjects at the 
follow up. The 104 drop outs at the follow up did not differ from participants regarding age, 
sex, work force participation, indication, educational level, comorbidity score and direct 
medical costs at baseline. 
Table 4: Baseline characteristics of the study population. Values are n (percentages) and means (SD). 
 
Variables (Baseline) Osteoarthritis Osteoporosis Back Pain Fibromyalgia Total 
N 97 98 143 72 410 
Female (%) 66 (68) 83 (84.7) 97 (67.8) 72 (100) 318 (77.6) 
Age (years) mean (SD) 66.56 (10.53) 66.85 (7.63) 52.91 (14.22) 53.49 (8.62) 59.57 (13.00) 
Subjects living in partnership 
(%) 
52 (53.6) 49 (50.0) 84 (58.7) 50 (69.4) 235 (57.3) 
Subjects with high educational 
level (%) 
36 (37.1) 34 (34.7) 70 (49.0) 10 (13.9) 150 (36.6) 
Subjects with paid work (%) 15 (15.46) 8 (8.16) 68 (47.55) 35 (48.6) 126 (30.73) 
Retired (%) 61 (62.9) 66 (67.3) 29 (20.3) 17 (23.6) 173 (42.2) 
 
The percentage of each cost component in the sum of direct medical costs is displayed in 
Table 5. The cost categories emergency services and aids and devices were contributing in 
all indications to less than 5% of the direct medical costs and therefore considered in this 
study as minor categories. Major cost categories were outpatient physician visits, non 
physician services, medication and inpatient treatment. 
Means estimated with all categories, as well as means estimated with major categories, are 
displayed in Table 6. Means and [95% CI] estimated with major categories are very similar 
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to the ones estimated with all categories. Since all 95% CI are overlapping, no statistic 
significant differences between the means can be inferred. 
Table 5: Percentages of health resource use categories in the sum of direct medical costs before and after a 
three week rehabilitation program. 
 
Osteoarthritis Osteoporosis Back Pain Fibromyalgia  Direct medical cost 
categories Before After Before After Before After Before After 
                 
Medication 47.29 31.49 62.04 69.99 26.07 43.69 13.75 18.99 
Non physician services 11.90 13.73 12.71 13.38 11.96 17.11 37.51 34.00 
Physician visits 25.12 18.46 12.13 14.61 27.66 20.71 31.8 28.37 
Inpatient treatment 12.16 33.52 11.98 0.97 29.86 16.46 13.91 17.12 
Aids and devices 3.53 2.69 0.52 1.01 2.14 2.03 1.71 1.29 
Emergency services 0 0.11 0.62 0.04 2.31 0 1.32 0.23 
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Table 6: Estimated means [95% confidence intervals] of direct medical costs calculated with major or with major and minor cost categories 12 months prior to rehabilitation 
and 12 months after rehabilitation. Means and bias corrected and accelerated confidence intervals were estimated with 1000 bootstrap replications. 
 
 Osteoarthritis (N=97) Osteoporosis (N=98) Back Pain (N=143) Fibromyalgia (N=72) 
Before 
Rehab 
Major and minor 
categories 
Major categories Major and minor 
categories 
Major categories Major and minor 
categories 
Major categories Major and minor 
categories 
Major categories 
         
Mean 1627.75 1510.85 2039.84 2023.85 2071.26 1963.00 4783.06 4663.04 
95% CI [1234.63; 2014.57] [1178.57; 1905.19] [1459.45; 2677.86] [1484.73; 2583.72] [1439.31; 2812.44] [1341.32; 2548.28] [3608.36; 6187.19] [3444.27; 6015.10] 
         
After 
Rehab 
Major and minor 
categories 
Major categories Major and minor 
categories 
Major categories Major and minor 
categories 
Major categories Major and minor 
categories 
Major categories 
         
Mean 1833.86 1725.25 2032.05 2030.63 1376.04 1523.03 3851.17 3894.07 





In this part of the doctoral thesis we aimed to identify major cost categories of direct medical 
costs among patients with musculoskeletal conditions undergoing rehabilitation programs. 
The main result is the identification of the following major categories: a) medication, b) 
physician visits, c) non physician services use and d) inpatient treatment. 
The assessment of economic outcomes in rehabilitation research of patients with a 
musculoskeletal condition has increased significantly in the past decade and the set of 
identified major direct medical cost categories has already been used to estimate costs. In 
back pain the inclusion of economic evaluations is widespread in rehabilitation studies 
targeting pre-post or between-group comparisons and the major categories medication, 
physician visits, non physician services use and inpatient treatment were frequently 
considered sufficient to estimate and compare direct medical costs [52-54, 77, 78]. Also a 
study targeting the cost of illness among fibromyalgia, back pain and ankylosing spondylitis 
patients used solely the cost categories described above to estimate direct medical costs 
[51]. In contrast, a review of 41 economic evaluations among patients with osteoarthritis 
and osteoporosis found a total of 34 direct medical cost categories used [34]. 
Comprehensive and extensive matrixes of applicable cost categories proposing relevant cost 
categories for cost evaluations have already been developed for musculoskeletal conditions 
[33, 34]. However, the selection of cost categories during the development of an economic 
evaluation depends strongly on the purpose of the study. Comprehensive core sets of cost 
categories are fundamental to perform cost-of-illness studies targeting the economic burden 
of a disease. In contrast, in economic evaluations alongside cohort studies, which are 
targeting either pre-post or between-group cost comparisons, brief core sets of most 
relevant cost domains including as many categories as necessary and as few as possible are 
recommended [36, 50].  
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Indeed, there are a number of arguments as to why it is advantageous to minimize the 
number of cost categories. Firstly, as economic evaluations are often piggyback studies 
alongside clinical studies, economic variables might be considered of secondary importance 
by clinical researchers [79]. We can therefore assume that instruments used to collect 
health resource use are more likely to be well-accepted by researchers and patients if they 
are as brief as possible. Secondly, cost data obtained using a brief core set of major direct 
medical cost categories can improve comparability across indications, which is of interest for 
public health policy makers and crucial in order to allow optimal allocation of resources. 
Thirdly, missing values are common even in carefully designed economic studies and 
become challenging in the analysis because of the highly skewed distribution of cost data 
[79]. As the direct medical cost is a sum of many cost categories, the probability of 
incomplete data, as well as the consequential need of complex imputation methods for 
generating “substitute” values, can be potentially diminished with the reduction of items in 
the sum.  
When interpreting our results, it is important to keep in mind that there is no standardized 
procedure to identify major direct medical cost categories. Indeed, we used an arbitrary cut-
off of 5% to discriminate major from minor important cost categories. This cut-off was in 
line with the purposes of our economic evaluations but is higher than another arbitrary cut-
off of 1% reported in the literature [53, 55]. However, while we tried to find major 
categories for four musculoskeletal indications, both of the mentioned studies focused on a 
single musculoskeletal condition [53, 55]. Including four different medical conditions in one 
sample required a higher cut-off in order to identify shared major categories. We have 
actually shown that estimated means do not importantly change if cost components 
contributing to less than 5% of the direct medical costs are excluded from the sum. 
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Our study has some limitations. Firstly, we used a self-report standardized questionnaire to 
collect retrospective information about health care resource, and this kind of data source is 
susceptible to recall bias and secondly, we extrapolated part of the costs to obtain annual 
figures conservatively assuming that resource use increases constantly. 
In summary, we have identified a) medication, b) physician visits, c) non physician services 
use and d) inpatient treatment as major direct medical cost categories for our sample 
including osteoarthritis, osteoporosis, back pain and fibromyalgia patients. The development 
of a standard brief core set of major direct medical cost categories for musculoskeletal 
conditions is important regarding the standardization and comparability of alongside 
economic evaluations. The major cost categories we identified can serve as candidate 
categories and contribute to enhance the process towards a standard brief core set of major 
cost categories for musculoskeletal conditions, which should be included in the alongside 
economic evaluation of rehabilitative interventions. 
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5. “Determinants of major direct medical cost categories among 
patients with osteoporosis, osteoarthritis, back pain and 
fibromyalgia undergoing outpatient rehabilitation” 
5.1. Objective 
The objective of this part of the doctoral thesis is the identification of determinants of direct 
medical costs among patients with osteoporosis, osteoarthritis, back pain and fibromyalgia 
undergoing outpatient rehabilitation. 
5.2. Material and Methods 
The present evaluation was performed alongside two cohort studies including patients with 
medical indications of fibromyalgia, osteoarthritis, osteoporosis or back pain undergoing 
outpatient rehabilitation at the Department of Physical Medicine and Rehabilitation of the 
University Hospital Munich. The study population is described in detail in section 4.2. 
The unifying framework of concepts and terminology proposed by the “International 
Classification of Functioning, Disability and Health” (ICF) was used as a basis for the 
selection of measures [2]. The ICF comprehensively covers all aspects of functioning, which 
encompasses body structures, body functions, activities and participation and is viewed in 
relation with the health condition, personal and environmental factors [80]. In order to 
cover health condition extensively we collected data about comorbidity using the self-
administered comorbidity questionnaire (SCQ) [81]. In order to cover body functions as 
well as activities and participations we used the eight scales (physical functioning, role 
physical, bodily pain, general health perception, vitality, social functioning, role emotional, 
mental health) of the SF-36 [82]. In order to cover personal factors demographic data was 
collected. Resource consumption was assessed with the self-report retrospective 
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questionnaire to collect health resource use reported in the first part of this doctoral thesis. 
Patients answered all questionnaires at baseline. 
Cost categories considered to calculate direct medical costs were outpatient physician 
services, non physician health services, medication and inpatient treatment. These categories 
were already identified in the second part of this doctoral thesis as being major direct 
medical cost categories in patients with fibromyalgia, osteoarthritis, osteoporosis or back 
pain. Resource use volumes were combined with unit costs to obtain a net cost per patient 
and extrapolated to obtain annual figures. Medication was valuated on the basis of prices of 
the online German drugs index book [74]. All other index costs were proposed by the 
Working Group Methods in Health Economic Evaluation (AG MEA) [43, 67, 68]. These 
index costs were extrapolated for 2004 using a factor of 0.025 for the first year and 0.020 for 
the following years. All costs were calculated in Euros for the year 2004. Due to the skewed 
distribution of cost data, we used non parametric bootstrap techniques with 1000 
replications to estimate means of costs and their 95% confidence intervals [95% CI]. Missing 
cost data was not imputed. 
To identify the determinants of direct medical costs we used two approaches. In order to 
address determinants of the distribution of direct medical costs a generalized linear model 
(GLM) with log link function and gamma distribution was performed. The Aikake 
Information Criterion (AIC) and the Pseudo-R² were used to select the best model and to 
address the explanatory power of the final model, respectively. Additionally, in order to 
gather a more meaningful interpretation of direct costs a multivariate logistic regression 
analysis was performed. Due to the usual skewed distribution of costs a suitable, meaningful 
and current cut-off to dichotomize direct medical costs into high versus low costs is the 
median of the known distribution [53, 62, 64]. Direct medical costs of more than €1333 
(median) were therefore defined as the outcome. A model including all variables of the final 
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GLM model and a final model using backwards selection were estimated. The area under the 
ROC curve was used to assess model accuracy in discriminating between high and low costs. 
The variable selection process included variables comprehensively assessing functioning. 
Health condition (medical indication, comorbidities), personal factors (age, education level, 
gender, living with a partner, SF36 general health perception), body functions (SF36 scales 
mental health, vitality and pain), activities and participations (work force participation, SF36 
scales physical functioning, role physical, role emotional and social functioning), and an 
environmental factor (type of rehabilitation care received) were considered. The correlation 
of each variable with costs was investigated in univariate analysis. Variables with a p-value 
lower than 0.25 were selected for further analysis. In a second step, a linear regression was 
performed in order to identify multicollinearity. A Variance Inflation Factor (VIF) higher 
than 2.5 was considered an indicator of multicollinearity. In order to guarantee the 
comparability of both regression models the evidence of a significant effect of an 
independent variable on costs either in the univariate GLM regression or in the univariate 
logistic regression was a criterion for including the variable in both regression models.  




Baseline characteristics of the 410 patients included in the study are described in Table 7. 
Table 7 Baseline characteristics of the sample.  
Values are n (percentages) or means (SD).  
 
Variables (Baseline) Osteoarthritis Osteoporosis Back Pain Fibromyalgia Total 
N 97 98 143 72 410 
Female (%) 66 (68) 83 (84.7) 97 (67.8) 72 (100) 318 (77.6) 
Age (years) mean (SD) 66.56 (10.53) 66.85 (7.63) 52.91 (14.22) 53.49 (8.62) 59.57 (13.00) 
Subjects living in 
partnership (%) 
52 (53.6) 49 (50.0) 84 (58.7) 50 (69.4) 235 (57.3) 
Subjects with high 
educational level (%) 
36 (37.1) 34 (34.7) 70 (49.0) 10 (13.9) 150 (36.6) 
Subjects with  
paid work (%) 
15 (15.46) 8 (8.16) 68 (47.55) 35 (48.6) 126 (30.73) 
Retired (%) 61 (62.9) 66 (67.3) 29 (20.3) 17 (23.6) 173 (42.2) 
Comorbidity Score (SCQ3) 
mean (SD) 
3.69 (2.43) 5.23 (2.94) 2.33 (2.74) 6.26 (3.52) 4.06 (3.23) 
SF-36 Physical Score 
mean (SD) 
31.97 (8.47) 37.19 (9.38) 34.86 (8.99) 30.40 (6.59) 33.96 (8.91) 
SF-36 Mental Score  
mean (SD) 
49.26 (10.42) 50.25 (9.58) 48.95 (10.69) 40.03 (12.28) 47.85 (11.18) 
 
Complete direct medical cost data was available at baseline for 72.16% osteoarthritis, 72.45% 
osteoporosis, 72.73% back pain and 77.78% fibromyalgia patients. The data set was complete 
regarding sex, age, medical indication and treatment, but values were missing (percentage of 
missing values) considering educational level (7.6%), participation at the work force (6.1%), 
comorbidity score (7.3%) and the SF-36 scales (between 7.85% and 10.2%). Since subjects 
with complete data sets (N=275) did not statistically significantly differ from subjects 
without complete data sets (N=135) regarding age, sex, educational level, participation at 
the work force and the comorbidity score, missing values can be supposed to be missing 
completely at random. However, multiple imputation techniques could not be used 
adequately due to the absence of high correlated covariates. The bias introduced by 
inadequately imputing missing data was therefore considered to be worse than the loss of 
                                                 
3
 SCQ, Self-administered comorbidity questionnaire. 
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power introduced by restricting the analysis to those observations with complete data. 
Hence, solely the 275 subjects (67%) with complete data were considered in the regression 
analysis.  
Direct medical costs and their components are displayed in Table 8. The univariate 
regression analyses are presented in Table 9. Neither the univariate GLM regression nor 
the univariate logistic regression showed any evidence that sex, marital status and treatment 
should be included in the final models. 
Table 8 Cost components and annual direct medical costs before rehabilitation. Values are means [95% bias 
accelerated and corrected confidence intervals] calculated with 1000 bootstrap samples.  
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The final multivariate GLM model and a logistic regression model including the same 
variables are presented in Table 10. In the final GLM regression model medical indication, 
age and the scales of the SF36 role physical, physical functioning, social functioning and 












 Values of cut-offs P-values P-values 
Demographics 
   
Sex Women NS NS 
Age continuous NS 0.032 
Education High educational 
level 
0.13 NS 
Work force participation Employed NS 0.020 
Living with a partner Living with a partner NS NS 
Interventional variables    
Treatment  
(outpatient or day care) 
Day care NS NS 
 
Disease related variables 
   






























Quality of Life 
   
SF36- physical functioning continuous < 0.001 0.004 
SF36- role physical continuous < 0.001 0.000 
SF36- physical pain continuous < 0.001 0.001 
SF36- general health 
perception 
continuous < 0.001 0.000 
SF36- vitality continuous < 0.001 0.000 
SF36- social functioning continuous < 0.001 0.000 
SF36- role emotional continuous < 0.001 0.001 




The explanatory power (Pseudo-R²) of the final GLM model was estimated to be 32.87%. In 
the final logistic regression model the medical indication fibromyalgia (OR=5.74, 95%CI 
2.051-16.066, p=0.001), the SF36 scale role physical (OR=0.988, 95%CI 0.980-0.996, 
p=0.002) and comorbidity (OR=1.161, 95%CI 1.043-1.292, p=0.006) were statistically 
significant determinants of high direct medical costs. The probability (estimated with ROC 
curves) that the final logistic model can correctly distinguish between low and high cost was 
estimated to be approximately 76.4%. 
Table 10 Multivariate models for prediction of direct medical costs. The table shows the final model of a 
generalized linear regression (GLM) with log link function and gamma distribution as well as a multivariate 
logistic regression model estimated with the same variables. In the logistic regression direct medical costs 
were dichotomized at the median of €1333. The probability estimated with ROC curve that this logistic model 
can correctly distinguish between low and high cost was 76.4%. 
 
 Linear outcome Dichotomized outcome 





Age 0.0125 0.0059 0.0344 1.031 1.003 – 1.060 0.030 
Indication       
     Osteoarthritis  Referent Referent 
     Osteoporosis 0.7265 0.1947 0.0002 1.412 0.590 – 3.377 0.439 
     Back pain 0.6247 0.1783 0.0005 1.962 0.864 - 4.453 0.107 
     Fibromyalgia 1.2775 0.2295 < 0.0001 6.208 2.060- 18.709 0.001 
Comorbidities 0.0288 0.0229 0.2076 1.157 1.033 - 1.296 0.012 
SF36- role physical -0.0074 0.0022 0.0006 0.988 0.978 - 0.998 0.014 
SF36- physical functioning -0.0073 0.0035 0.0365 1.007 0.990 – 1.025 0.422 
SF36- mental health -0.0095 0.0050 0.0585 0.986 0.965 – 1.008 0.214 
SF36- vitality 0.0137 0.0050 0.0058 1.013 0.990 – 1.037 0.266 
SF-36 social functioning  -0.0071 0.0036 0.0477 0.990 0.975 – 1.005 0.181 
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We found that age, medical condition, comorbidities and various aspects of functioning may 
explain direct medical costs. Our results are largely consistent with the determinants 
identified in previous studies examining the direct medical costs of single conditions. 
Additionally, our work is the first to show in a direct comparison the magnitude of the 
economic burden related to fibromyalgia. 
An important aspect of our work was the examination of the determinants of high medical 
costs as defined beyond the median value €1333. Differing from the analysis of direct 
medical costs using linear regression modelling, we found that comorbidity seems to play an 
important role and may actually be more important than some additional aspects of physical 
functioning beyond role physical. This indicates that optimal medical management of 
comorbidities is a corner stone in reducing high direct medical costs in comprehensive 
rehabilitation programs.  
When comparing our results with the literature it is important to keep in mind that we 
considered four musculoskeletal conditions while published studies looked for predictors of 
costs regarding a single condition. Results of previous studies are therefore not directly 
comparable with ours. Indeed, medical condition was one of the strongest predictors of 
direct medical costs in this work. This result is consistent with a similar study targeting 
determinants of overall costs (direct medical and indirect costs) across three musculoskeletal 
conditions, which found the medical condition to be the single predictor of costs [51]. In 
fact, only studies including many musculoskeletal disorders enable a direct and unbiased 
comparison of the economic burden of musculoskeletal diseases.  
Predictors of direct costs identified in the present work are generally in line with available 
literature. We identified age as a statistically significant predictor of direct medical costs, 
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which did not achieve significance in the final model addressing direct medical costs beyond 
the median. Indeed, age was identified as a significant predictor of direct medical costs in 
patients with RA [60] but this variable was dominated by functional status and other 
determinants in studies addressing direct medical costs beyond the median [62, 64]. 
Associations between the scales of the SF 36 and direct medical costs are consistent with the 
available literature: poor scores in subscales of the SF 36  were significantly associated with 
the magnitude of direct costs incurred by OA patients [66] as well as with higher direct 
costs among RA patients [61]. Considering that the SF-36 is measuring similar constructs 
as the HAQ, WOMAC and FIQ [5, 83], our results are in line with studies addressing a 
single musculoskeletal condition, which found functional status, measured by disease-specific 
health related quality of life instruments, to be a reliable predictor of direct costs [5, 56-61, 
63-65, 84].  
The presence of comorbidity is an important predictor of costs among fibromyalgia patients 
[59, 63, 64]. However, the impact of comorbidity on direct costs is still unclear among other 
musculoskeletal conditions. In a study including over 7000 patients with RA comorbidity 
was, after the HAQ, the second strongest predictor of costs among clinical variables [60]. In 
contrast, among RA and OA patients, comorbidity did not remain in the final model 
explaining costs [61, 62, 66]. In two of these studies SF-36 scales were identified as strong 
predictors of direct costs [62, 66], which comes close to our results. The SF-36 scales are 
powerful determinants of direct costs and might have dominated comorbidity in explaining 
the magnitude of costs in our work. Comorbidity was in contrast, statistically a highly 
significant predictor of direct medical costs beyond the median in the present study. Since 
literature addressing the impact of comorbidity on direct medical costs beyond the median is 
scarce and contradictory, our results are hardly comparable. Among RA patients stratified 
by disease duration, comorbidity did not remain in the final model while functional disability 
(HAQ) was the strongest variable associated with direct costs beyond the median [62]. On 
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the contrary, the presence of many comorbidity conditions was strongly associated with 
costs beyond the median among  women with fibromyalgia [64]. 
Our results raise the question of what to target when designing cost-saving rehabilitation 
programs. In order to reduce high direct medical costs in the long term, rehabilitation 
programs need to focus rather on the societal perspective of functioning represented by the 
involvement in life situations like daily routine, instead of focusing on the individual 
perspective of functioning represented by the execution of a task or action by an individual. 
Additionally, adequate disease management programs for patients with comorbidities need 
to be assured since the presence of coexisting conditions were shown to exert a powerful 
influence on the incurrence of direct medical costs beyond the median. Finally, as the 
medical indication fibromyalgia was the outstanding determinant of direct medical costs 
beyond the median in our population, fibromyalgia should be targeted as a major public 
health issue. 
This work has some limitations. Firstly, we used a self-report retrospective standardized 
questionnaire to collect information on health care resources and this kind of data source is 
susceptible to recall bias. Secondly, we extrapolated a part of the costs to obtain one year 
figures conservatively assuming that resource use increases constantly. Thirdly, we decided 
to perform regression analysis only with complete data sets. However, the bias introduced 
by inadequately imputing missing data was considered to be worse than the loss of power 
introduced by restricting the analysis to those observations with complete data. Fourthly, 
regarding the comparison between high and low costs it would also be meaningful to 
compare the first quarter of the distribution of direct medical costs with the last quarter but 
this was not possible due to our sample size. Finally, it is also important to notice that the 
loss of power due to dichotomization of our dependent variable could be one reason the 
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scales of the SF36 physical functioning, social functioning and vitality did not remain in the 
final logistic regression model. 
In summary, in our population almost the whole spectrum of functioning including body 
functions (SF36 scale vitality) as well as activities and participation (SF36 scales physical 
functioning, role physical and social functioning) in relation to the health condition (medical 
indication) and a personal factor (age) is needed to explain the distribution of direct medical 
costs. In predicting direct costs beyond the median, health condition (fibromyalgia, 
comorbidity) and an important participation component regarding how patients function in 





In this doctoral thesis an instrument to collect health resource utilization has been described 
and major direct medical cost categories, as well as determinants of direct medical costs for 
our sample including osteoarthritis, osteoporosis, back pain and fibromyalgia patients, have 
been identified.  
Due to the limitability of health resources and permanently rising health care costs related 
to musculoskeletal diseases, health care and pension fund insurances are increasingly 
interested in alongside economic evaluations of new interventions in the field of 
rehabilitation. However, clinical researchers are often overstretched by the need to perform 
an alongside economic evaluation because firstly, there are almost no questionnaires 
available for the collection of routine health care resource use data; secondly, major direct 
medical cost categories capable of performing pre-post or between-group comparisons 
alongside clinical studies are not clearly defined, and thirdly, what to target in a 
rehabilitation program, in order to avoid the incurrence of excessive and avoidable costs 
after discharge, is also often not clearly defined. 
In the first part of this doctoral thesis we describe an instrument to collect health resource 
utilization. The instrument proved to be satisfactory and provided enough information to 
calculate direct medical, direct non medical and indirect costs. A core version of this 
instrument omitting disease-specific aspects could serve as a starting point towards a 
standardized and validated, general, self-administered questionnaire suitable for economic 
evaluations in rehabilitation.  
In the second part of this doctoral thesis we identified medication, physician visits, non-
physician service and inpatient treatment as major direct medical cost categories for our 
sample, including osteoarthritis, osteoporosis, back pain and fibromyalgia patients. The 
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development of a standard brief core set of major direct medical cost categories for 
musculoskeletal conditions is important regarding the standardization and comparability of 
comparative economic evaluations. The major cost categories we identified can serve as 
candidate categories and enhance the process towards a standard brief core set of major cost 
categories for musculoskeletal conditions. This should be included in the alongside economic 
evaluation of rehabilitative interventions targeting pre-post or between-group comparisons. 
In the last part of this doctoral thesis we showed that in our population almost the whole 
spectrum of functioning is needed to explain the distribution of direct medical costs. In 
predicting high direct costs beyond the median, health condition (fibromyalgia, comorbidity) 
as well as an important participation component regarding how patients function in their 
daily activities as a result of physical health (SF 36 role physical) remained strong 
predictors. Owing to our results and in order to reduce high direct medical costs in the long 
term, rehabilitation programs need to focus on the societal perspective of functioning 
represented by involvement in life situations like daily routine instead of focusing on the 
individual perspective of functioning represented by the execution of a task or action by an 
individual. Additionally, adequate disease management programs for patients with 
comorbidities need to be assured since the presence of coexisting conditions showed to exert 
a powerful influence on the incurrence of direct medical costs beyond the median. Finally, as 
the medical indication fibromyalgia was the outstanding determinant of direct medical costs 






Musculoskeletal disorders affect hundreds of millions of people around the world and are 
related to important limitations in functioning. The economic burden related to medical 
treatment of subjects with musculoskeletal chronic diseases is therefore substantial. 
Rehabilitation of patients suffering from osteoarthritis, osteoporosis, back pain or 
fibromyalgia is essential and achieves its goal by supporting patients in achieving and 
maintaining an optimal level of functioning. Due to the economic burden related to these 
diseases and the limitations of health resources, an additional task of rehabilitative 
interventions is the reduction of excessive direct costs related to inappropriate disease 
management. When designing studies targeting the effectiveness of rehabilitation programs 
for musculoskeletal patients it is therefore essential to provide conditions necessary to 
perform sound economic evaluations targeting also the cost-effectiveness of such 
interventions. 
In order to provide conditions necessary to perform economic evaluations alongside studies 
targeting the effectiveness of rehabilitation programs, it is essential to define how health 
care resource utilization should be measured. It is also crucial to identify which health 
resource utilization domains are relevant and sufficient to estimate reliable figures of costs in 
order to perform pre-post or between-group cost analyses. Finally, when designing 
rehabilitation programs for musculoskeletal patients targeting not only an optimal level of 
functioning but also the reduction of excessive and avoidable costs related to medical 
treatment, it is important to consider which factors are determining such costs in order to 




The overall objective of this doctoral thesis is to address some of the conditions necessary to 
routinely perform alongside economic evaluations of rehabilitation programs. The specific 
aims are to 1) present a standardized instrument to collect data about health care resource 
use, 2) identify major cost categories of direct medical costs to be used in comparative 
economic evaluations of subjects with musculoskeletal diseases and 3) identify determinants 
of direct medical costs among subjects with musculoskeletal diseases. This thesis is therefore 
subdivided into three parts. In the first part the development of a standardized instrument to 
collect health care resource use in the context of rehabilitation is described and lessons 
learned are discussed. In the next part major direct medical costs categories among patients 
with musculoskeletal conditions undergoing outpatient rehabilitation are identified. Lastly, 
the determinants of the direct medical costs as well as direct medical costs beyond the 
median incurred by chronic musculoskeletal patients are examined. Each of these parts 
contain a specific discussion section referring to its specific results. 
“Development of an instrument to collect health care resource use data in the context 
of rehabilitation” 
The objective of this part of the doctoral thesis is to describe the development of an 
instrument to collect health resource utilization data in rehabilitation research and to 
discuss lessons learned. The questionnaire was developed to collect data about health 
resource use aiming at the alongside economic evaluations of five rehabilitation studies. 
Considering the health condition of study patients, the specific questions of associated 
studies and the methodological standards proposed by the “Working Group Methods in 
Health Economic Evaluation” (MEA), it was decided which health resource use components 
should be part of the questionnaire and which recall period would be adequate. Health 
resource use information was assessed in order to calculate direct medical, direct non 
medical and indirect costs. The standardized self administered retrospective health resource 
  
 51 
use assessment questionnaire was answered by a total of 1042 subjects with one of the 
following indications: osteoarthritis, osteoporosis, back pain, cancer, fibromyalgia or 
brain/cranial traumata. Although the questionnaire was adapted for each rehabilitation 
study, it could be learned that the development of a standardized general brief questionnaire 
to collect health resource use with fixed cost categories is of fundamental importance in 
order to facilitate comparability across indications and studies in rehabilitation. The 
instrument to collect health resource utilization provided enough information to calculate 
direct medical, direct non medical and indirect costs. The core version omitting disease-
specific aspects could serve as a starting point towards a standardized and validated, general, 
self-administered questionnaire suitable for alongside comparative economic evaluations in 
rehabilitation. 
“Identification of major direct medical cost categories among patients with 
musculoskeletal conditions undergoing outpatient rehabilitation” 
In economic evaluations brief core sets of most relevant cost domains, including as 
many categories as necessary and as few as possible, are recommended, alongside cohort 
studies, which target either pre-post or between-group cost comparisons. The goal of 
this part of the doctoral thesis was to identify major cost categories of direct medical 
costs among patients with musculoskeletal conditions undergoing a rehabilitation 
program. Minor cost categories were discriminated from major cost categories by 
ranking the percentage of direct medical costs represented by each category using a cut 
off of 5%. Means and 95% confidence intervals [95% CI] of direct medical costs were 
estimated either with major and minor or solely with major cost categories using 1000 
bootstrap samples. Major cost categories for our sample including osteoarthritis, 
osteoporosis, back pain and fibromyalgia patients were outpatient physician visits, non 
physician services, medication and inpatient treatment. Since the 95% confidence 
intervals of estimated means were overlapping, no statistically significant difference can 
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be assumed between the mean direct medical costs estimated solely with major 
categories and the one estimated with all available categories The development of a 
standard brief core set of major direct medical cost categories for musculoskeletal 
conditions is important regarding the standardization of comparative economic 
evaluations. The major cost categories we identified can serve as candidate categories 
and make a valuable contribution to the establishment of a standard brief core set of 
major cost categories for musculoskeletal conditions which should be included in the 
alongside economic evaluation of rehabilitative interventions. 
“Determinants of major direct medical cost categories among patients with 
osteoporosis, osteoarthritis, back pain and fibromyalgia undergoing outpatient 
rehabilitation” 
The goal of this part of this doctoral thesis was to identify determinants of direct medical 
costs among patients with osteoporosis, osteoarthritis, back pain or fibromyalgia patients 
undergoing outpatient rehabilitation. The sample consisted of 410 patients. In order to 
identify determinants of direct medical costs a generalized linear model (GLM) with log link 
function and gamma distribution as well as a multivariate logistic regression analysis were 
performed. A total of 275 (67%) subjects with complete data sets were considered in the 
regression analysis. In the final GLM regression model medical indication, age and the 
scales of the SF36 role physical, physical functioning, social functioning and vitality were 
significant predictors of direct medical costs. In the final logistic regression model medical 
indication, the SF36 scale role physical and comorbidity were significant determinants of 
high direct medical costs beyond the median. This work confirms known predictors of the 
distribution of direct medical costs and broadens the understanding of determinants of direct 
medical costs beyond the median. The need to comprehensively address patient problems, 
including optimal medical management of comorbidities as well as the need to focus on the 
societal perspective of functioning, are core issues in designing cost-saving rehabilitation 
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programs. Additionally, the medical indication fibromyalgia, which was the outstanding 
determinant of high direct medical costs in our population, should be targeted as a major 
public health issue. 
Conclusion 
In the first part of this doctoral thesis we proposed an instrument to collect health resource 
utilization. The instrument was answered satisfactorily and provided enough information to 
calculate direct medical, direct non medical and indirect costs. A core version of this 
instrument omitting disease-specific aspects could serve as a starting point towards a 
standardized and validated general self-administered questionnaire suitable for economic 
evaluations in rehabilitation.  
In the second part of this doctoral thesis we identified medication, physician visits, non 
physician services use and inpatient treatment as major direct medical cost categories for 
our sample including osteoarthritis, osteoporosis, back pain and fibromyalgia patients. The 
major cost categories we identified can serve as candidate categories and contribute to 
enhance the process towards a standard brief core set of major cost categories for 
musculoskeletal conditions, which should be included in the economic evaluation of 
rehabilitative interventions targeting pre-post or between-group comparisons. 
In the last part of this doctoral thesis we showed that, in our population, almost the whole 
spectrum of functioning is needed to explain the distribution of direct medical costs. In 
predicting high direct costs beyond the median health condition (fibromyalgia, comorbidity) 
as well as an important participation component regarding how patients function in their 
daily activities as a result of physical health (SF 36 role physical) remained strong 
predictors. Owing to our results and in order to reduce high direct medical costs in the long 
run, rehabilitation programs need to focus rather on the societal perspective of functioning 
represented by the involvement in life situations like daily routine, instead of focusing on the 
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individual perspective of functioning represented by the execution of a task or action by an 
individual. Additionally, since the presence of coexisting conditions showed to exert a 
powerful influence on the incurrence of direct medical costs beyond the median, appropriate 
disease management programs for patients with comorbidities need to be assured. Finally, as 
the medical indication fibromyalgia was the outstanding determinant of direct medical costs 






Millionen von Menschen in der ganzen Welt leiden unter einer oder mehreren 
muskuloskeletalen Erkrankungen und erleben deswegen erhebliche Beeinträchtigungen in 
ihrer Funktionsfähigkeit. Die sozialökonomischen Konsequenzen, welche mit der 
medizinischen Behandlung von muskuloskeletalen Erkrankungen zusammenhängen, sind 
daher beträchtlich. Die Rehabilitation von Menschen mit Erkrankungen wie zum Beispiel 
Osteoarthrose, Osteoporose, Rückenschmerzen und Fibromyalgia ist daher von großer 
Bedeutung.  
Ziel der Rehabilitation ist es, Betroffene zu unterstützen, ein optimales Niveau der 
Funktionsfähigkeit zu erreichen und dieses aufrecht zu erhalten. Aufgrund der 
sozialökonomischen Konsequenzen verbunden mit der Erkrankung und der Knappheit von 
Ressourcen im Gesundheitswesen, ist ein weiteres Ziel der Rehabilitation die Reduktion von 
exzessiven direkten medizinischen Kosten. Diese Kosten sind meistens auf ineffiziente 
Behandlungsstrategien zurückzuführen. Es ist deshalb bedeutsam, das Ziel „Reduktion von 
exzessiven direkten medizinischen Kosten“ schon bei der Entwicklung von neuen 
Rehabilitationsprogrammen zu berücksichtigen und die Voraussetzungen für die 
Durchführung von begleitenden ökonomischen Evaluationen, meistens Kosten-
Wirksamkeits-Analysen, schon bei der Planung von klinischen Studien zu schaffen. 
Um begleitende ökonomische Evaluationen klinischer Studien im Bereich der Rehabilitation 
zu ermöglichen, ist es sehr wichtig zu definieren, wie Ressourcenverbrauchsdaten erhoben 
werden sollen. Es ist ebenfalls wichtig zu definieren, welche Kostenkomponenten relevant 
und ausreichend für die Durchführung von vergleichenden gesundheitsökonomischen 
Analysen sind. Ebenfalls sollen bei der Entwicklung von Rehabilitationsprogrammen, 
welche nicht nur eine optimale Funktionsfähigkeit, sondern auch eine Reduktion von 
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exzessiven und vermeidbaren direkten Kosten anstreben, Determinanten von solchen 
Kosten berücksichtigt werden. 
Ziele 
Das allgemeine Ziel dieser Doktorarbeit ist es, einigen der notwendigen Voraussetzungen 
für die routinemäßige Durchführung von begleitenden gesundheitsökonomischen 
Evaluationen zu untersuchen. Die spezifischen Ziele sind 1) ein Instrument zur Erfassung 
von Ressourcenverbrauch zu präsentieren sowie 2) die für vergleichende ökonomische 
Evaluationen bedeutenden direkten medizinischen Kostenkategorien in einer 
Patientengruppe mit muskuloskeletalen Erkrankungen und 3) Determinanten von direkten 
medizinischen Kosten in einer Patientengruppe mit muskuloskeletalen Erkrankungen zu 
identifizieren.  
Diese Doktorarbeit wurde wegen der spezifischen Ziele in drei Teilen strukturiert. Im 
ersten Teil wird die Entwicklung eines Instrumentes zur Erhebung von 
Ressourcenverbrauch dargestellt und die damit verbundenen Erfahrungen und Erkenntnisse 
werden diskutiert. Im zweiten Teil werden bedeutende direkte medizinische 
Kostenkategorien, welche in begleitenden und vergleichenden gesundheitsökonomischen 
Evaluationen von Interventionen für Patienten mit muskuloskeletalen Erkrankungen 
herangezogen werden sollen, identifiziert. Zum Schluss werden Determinanten von direkten 
medizinischen Kosten aber auch von direkten medizinischen Kosten jenseits des Median 
identifiziert. Jeder Teil dieser Doktorarbeit beinhaltet eine eigene Diskussion, die zu der 
spezifischen Ergebnissen gehört. 
“Entwicklung eines Instrumentes zur Erfassung von Ressourcenverbrauch in der 
Rehabilitation” 
Ziel dieses Teils der Doktorarbeit ist die Beschreibung der Entwicklung eines Instrumentes 
zur Erhebung des Ressourcenverbrauchs in der Rehabilitation sowie die Diskussion unserer 
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Erfahrungen und Erkenntnisse. Ziel der Entwicklung des Instruments war die Erhebung 
des Ressourcenverbrauchs mehrerer Rehabilitationsstudien, wofür eine begleitende 
gesundheitsökonomische Evaluation vorgesehen war. Die Entscheidung, welche 
Kostenkomponenten erfasst werden sollen und welcher Detaillierungsgrad bevorzugt 
werden sollte, wurde anhand der Indikation, der spezifischen Fragestellung der Studie sowie 
der methodologischen Empfehlungen der „Arbeitsgruppe Methoden der 
gesundheitsökonomischen Evaluation“ (MEA) entschieden. Der Ressourcenverbrauch 
wurde mit dem Ziel erhoben, direkte medizinische und nicht medizinische sowie indirekte 
Kosten berechnen zu können. Das Instrument zur Erfassung des Ressourcenverbrauchs 
wurde von insgesamt 1042 Patienten, die entweder an Osteoarthritis, Osteoporose, 
Rückenschmerzen, Krebs, Fibromyalgia oder Schädel-Hirntrauma erkrankt waren, 
ausgefüllt. Obwohl das Instrument für jede Studie angepasst wurde, sind wir der Meinung, 
dass die Entwicklung eines kurzen, standardisierten und generellen Instruments zur 
Erfassung des Ressourcenverbrauchs in der Rehabilitation von großer Bedeutung bezüglich 
der Vergleichbarkeit zwischen Studien und Indikationen sein könnte. Ausreichende Daten 
zur Berechnung von direkten und indirekten Kosten konnten mit dem Instrument zur 
Erfassung des Ressourcenverbrauchs gewonnen werden. 
„Identifikation von primär bedeutenden direkten medizinischen Kostenkategorien bei 
Patienten mit muskuloskeletalen Erkrankungen“ 
Ziel des zweiten Teils der Doktorarbeit ist es, primär bedeutende direkte medizinische 
Kostenkategorien in einer Population mit muskuloskeletalen Erkrankungen, welche sich 
am Anfang eines ambulanten Rehabilitationsprogramms (Tagesklinik) befindet, zu 
identifizieren. Der Bedeutungsgrad von Kostenkategorien wurde ermittelt, indem der 
Prozentanteil jeder Kostenkategorie in der Berechnung der direkten medizinischen 
Kosten ermittelt wurde. Eine Grenze von 5% sollte sekundäre von primären 
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Kostenkategorien unterscheiden. Mittelwerte und 95% Konfidenzintervalle [95% KI] 
der direkten medizinischen Kosten mit allen Kostenkategorien oder nur mit primär 
bedeutenden Kostenkategorien wurden mittels Bootstraping mit 1000 Replikationen 
geschätzt. Primär bedeutende Kostenkategorien in unserer Studienpopulation mit 
entweder Osteoporose, Osteoarthritis, Rückenschmerzen oder Fibromyalgia waren 
ambulante Arztkonsultationen, therapeutische Leistungen, Medikation und stationäre 
Behandlung im Krankenhaus. Die Mittelwerte [95% KI] berechnet mit und ohne 
sekundär bedeutenden Kostenkategorien waren sehr ähnlich. Die primären 
Kostenkategorien, welche in dieser Arbeit identifiziert wurden, können als 
Kandidatenkategorien eines standardisierten summarischen „Core Set“ primär 
bedeutender direkter medizinischer Kostenkategorien dienen, welche in vergleichenden 
gesundheitsökonomischen Analysen verwendet werden können. 
“Determinanten primär bedeutender direkt medizinischer Kostenkategorien in einer 
Patientenpopulation mit Osteoporose, Osteoarthrose, Rückenschmerzen oder 
Fibromyalgia” 
Ziel dieses Teils der Doktorarbeit ist es, Determinanten von primären direkt medizinischen 
Kostenkategorien in einer Patientenpopulation mit Osteoporose, Osteoarthrose, 
Rückenschmerzen oder Fibromyalgia, welche in einer ambulanten Rehabilitation behandelt 
wurden, zu identifizieren. Insgesamt wurden 410 Patienten eingeschlossen. Um 
Determinanten direkter medizinischer Kosten zu identifizieren, wurden ein generalisiertes 
lineares Modell (GLM) mit log link Funktion und Gamma Verteilung sowie eine logistische 
Regression durchgeführt. Insgesamt wurden 275 (67%) Patienten in den 
Regressionsanalysen berücksichtigt. Im Endmodell des GLM wurden Indikation, Alter und 
die SF-36 Skalen körperliche Rollenfunktion, physische Funktion, soziale Funktion und 
Vitalität als signifikante Determinanten der Verteilung direkter medizinischer Kosten 
identifiziert. Im Endmodell der logistischen Regression wurden Indikation, die Skala 
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körperliche Rollenfunktion des SF-36 sowie Komorbidität als Determinanten von hohen 
direkten medizinischen Kosten jenseits des Median identifiziert. Diese Arbeit bestätigt 
bekannte Determinanten von direkten medizinischen Kosten und untermauert die 
Notwendigkeit einer umfassenden Behandlungsstrategie in der Rehabilitation. Optimales 
medizinisches Management von Komorbiditäten sowie Rehabilitationsprogramme, die 
hauptsächlich auf die soziale Perspektive der Funktionsfähigkeit abzielen, sind erforderlich, 
um exzessiven direkten medizinischen Kosten entgegenzuwirken. Die Indikation 
Fibromyalgia, die eine bedeutende Determinante von erhöhten direkten medizinischen 
Kosten in unserer Population war, sollte als ein wichtiges Thema öffentlicher Gesundheit 




Im ersten Teil dieser Doktorarbeit wurde ein Instrument zur Erhebung von 
Ressourcenverbrauch dargestellt. Das Instrument wurde gut akzeptiert und lieferte 
ausreichend Information, um direkte medizinische, direkte nicht medizinische und indirekte 
Kosten zu berechnen. Eine reduzierte Version dieses Instrumentes ohne 
krankheitsspezifische Aspekte könnte als Startpunkt der Entwicklung eines standardisierten 
und validierten nicht krankheitsspezifischen Instruments für die Erfassung von 
Ressourcenverbrauch in gesundheitsökonomische Evaluationen in der Rehabilitation dienen. 
Im zweiten Teil dieser Dissertation werden ambulante Arztkonsultationen, therapeutische 
Leistungen, Medikation und stationäre Behandlung im Krankenhaus als primär bedeutende 
direkte medizinische Kostenkategorien in einer Patientenpopulation mit Osteoporose, 
Osteoarthrose, Rückenschmerzen oder Fibromyalgia identifiziert. Diese Kostenkategorien 
können als Startpunkt dienen, um ein standardisiertes summarisches „Core Set“ primär 
bedeutender direkter medizinischer Kostenkategorien zu entwickeln, welches in 
begleitenden und vergleichenden gesundheitsökonomischen Analysen verwendet werden 
kann. 
Im letzten Teil dieser Dissertation, Alter und die SF-36 Skalen körperliche Rollenfunktion, 
körperliche Funktion, sozialer Funktion und Vitalität wurden als signifikante 
Determinanten der Verteilung direkter medizinischer Kosten identifiziert während 
Indikation, die Skala körperliche Rollenfunktion des SF-36 sowie Komorbidität als 
Determinanten von erhöhten direkten medizinischen Kosten jenseits des Median 
identifiziert wurden. Um positive sozioökonomische Outcomes zu erreichen, müssen 
Behandlungsstrategien in der Rehabilitation umfassend sein. Die soziale Perspektive der 
Funktionsfähigkeit oder Teilhabe sollte mehr Gewicht bekommen als die individuelle 
Perspektive der Funktionsfähigkeit. Ein optimales medizinischen Management von 
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Komorbiditäten ist ebenfalls erforderlich, um exzessiven direkten medizinischen Kosten 
entgegenzuwirken. Schließlich, die Indikation Fibromyalgia, die eine bedeutende 
Determinante von erhöhten direkten medizinischen Kosten in unserer Population war, sollte 
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Fragebogen zur Erfassung von Ressourcenverbrauch 
 
Study: Feasibility of the Willingness-to-pay methodology for expected and perceived health 
effects 





Gesundheitsökonomische Beratungsstelle der  




Fragebogen zur Erfassung von Ressourcenverbrauch 
12 Monate vor der Rehabilitation 
 
1. Waren Sie innerhalb der letzten 4 Wochen beim Arzt (Praxis) wegen Ihrer Erkrankung? 
 Nein   Ja. Falls ja, kreuzen Sie bitte an bei welchem: 
 
 Fachrichtung Wie oft? 








Facharzt für : 
 
_______________________________ Mal 
Welches Verkehrsmittel haben Sie auf dem Weg zu 
Ihrer Arztbesuche benutzt? 
Kosten der Fahrten 
insgesamt, falls bekannt  





 Privat Pkw 
 
 
2. Sind Sie in den letzten 12 Monaten im Krankenhaus in einer Tagesklinik wegen Ihrer 
Erkrankung behandelt worden? 
 Nein   Ja. Wenn ja: 
 
In welcher Klinik? Fachabteilung  Wegen Wie lange? 
   
Tage 

























Welches Verkehrsmittel haben Sie auf dem Weg zu 
Ihrer Tagesklinikbehandlung benutzt? 
Kosten der Fahrten insgesamt, falls 
bekannt 









3. Sind Sie in den letzten 12 Monaten im Krankenhaus stationär wegen Ihrer Erkrankung 
behandelt worden? 




Krankenhaus? Fachabteilung  Wegen Wie lange? 
   
Tage 




4. Sind Sie in den letzten 12 Monaten im Krankenhaus ambulant ärztlich wegen Ihrer Erkrankung 
behandelt worden? 
 Nein   Ja. Wenn ja: 
 
 
In welcher Klinik? Fachabteilung  Wegen Wie lang? 
   
Tage 
   
Tage 
Welches Verkehrsmittel haben Sie auf dem Weg zu 
Ihrer ambulanten Behandlung benutzt? Kosten insgesamt, falls bekannt 









5. Haben Sie in den letzten 12 Monaten wegen Ihrer Erkrankung an einer Selbsthilfegruppe 
teilgenommen? 
 








6. Haben Sie in den letzten 6 Monaten einen Notdienst aufgrund Ihrer Erkrankung in Anspruch 
genommen? 
 
 Nein, ich habe keinen Notdienst in Anspruch genommen 
 Ja, ich wurde im Krankenhaus in einer Notfallambulanz behandelt. Wie oft? _____ 
 Ja, ich habe einen Bereitschaftsarzt zu Hause benötigt. Wie oft? _____ 
 Ja, ich habe einen Krankenwagen nur mit Sanitätern benötigt. Wie oft? _____ 
 Ja, ich habe einen Krankenwagen mit Sanitätern und Notarzt benötigt. Wie oft? _____ 
 
 
7. Haben Sie in den letzten 12 Monaten ambulante therapeutische Leistungen wegen Ihrer 
Erkrankung in Anspruch genommen? 
 Nein   Ja. Falls ja, kreuzen Sie bitte an welche: 
 










 Psychologische Behandlung 
Mal 








Welches Verkehrsmittel haben Sie auf dem Weg zu Ihrer 
Therapie benutzt? 
Kosten der Fahrten insgesamt, 
falls bekannt 
 














8. Haben Sie in den letzten 6 Monaten eine Hilfsmittelversorgung (z. B. Gehhilfe, Rollstuhl, 
Schienen, Bandagen, Einlagen) wegen Ihrer Erkrankung in Anspruch genommen? 
 
 Nein   Ja. Wenn ja: 
 
Welche Hilfsmittel? Kosten insgesamt, falls bekannt 





 ja, einen Teil der Kosten 




 ja, einen Teil der Kosten 
 ja, Gesamtkosten 
 
 
9. Besitzen Sie einen Schwerbehindertenausweis? 
 
 Nein   Ja mit Behinderungsgrad: _______% Welches Merkzeichen?_____ 
 
 
10. Haben Sie innerhalb der letzten 4 Wochen Medikamente eingenommen? Falls ja, legen Sie bitte 
einen Teil der Medikamentenverpackung bei, aus dem der Name des Medikamentes ersichtlich 
ist. 
 Nein   Ja. Wenn ja: 
 
Wie viele Tabletten am Tag Ärztlich verschriebene Medikamente 
 
Name 






   
3. 
   
4. 
   
5. 
   
Wie viele Tabletten am Tag Selbstgekaufte Medikamente (ohne Verschreibung) 
 






   
3. 
   
 
 




12. Wenn Sie an Ihre Erkrankung denken: Haben Ihnen Angehörige oder Freunde/Bekannte in den 
letzten 4 Wochen geholfen? 





Woche? Was wurde gemacht? 
 Bei pflegerischen Leistungen   
 Bei Arztbesuchen/ Therapien   
 Bei der Besorgung von Medikamente   







13. Haben Sie in den letzten 12 Monaten einen Rentenantrag gestellt? 
 
 Nein, ich bin schon Rentner 
 Nein, ich habe keinen Antrag gestellt 
 Ja, der Antrag wurde aber noch nicht bewilligt  






14. Konnten Sie wegen Ihrer Erkrankung in den letzten 12 Monaten nicht arbeiten? 
 
 Nein   Ja. Falls ja, waren Sie: 
 
 Zustand Wie lange? 
 Krankgeschrieben mit ärztlichem Attest 
Tage 
 Krank, aber ohne ärztliches Attest Tage 
 Von der Arbeit abwesend (z. B. wegen 
Arztbesuche oder Krankengymnastik) Stunden 
 
Wenn Sie erwerbstätig sind: Bitte beantworten Sie noch Frage 14 und 15. 
 
Wenn Sie nicht erwerbstätig sind: Der Fragebogen ist hier beendet. 




15. Haben Sie in den letzten 12 Monaten wegen Ihrer Erkrankung an einer der folgenden beruflichen 
Maßnahmen teilgenommen? 
 Nein   Ja. Falls ja, kreuzen Sie an welche: 
 
 Maßnahme Wie lange? Wer hat die Maßnahme finanziert? 
 Umschulung 
Wochen 



















Gesundheitsökonomische Beratungsstelle der  




Fragebogen zur Erfassung von Ressourcenverbrauch 
6 Monate nach der Rehabilitation 
 
 
1. Waren Sie innerhalb der letzten 4 Wochen beim Arzt (Praxis) wegen Ihrer Erkrankung? 
 Nein   Ja. Falls ja, kreuzen Sie bitte an bei welchem: 
 
 Fachrichtung Wie oft? 








Facharzt für : 
 
_______________________________ Mal 
Welches Verkehrsmittel haben Sie auf dem Weg zu 
Ihrer Arztbesuche benutzt? 
Kosten der Fahrten 
insgesamt, falls bekannt  
 





 Privat Pkw 
 
 
2. Sind Sie seit Ihrer Rehabilitation im Krankenhaus in einer Tagesklinik wegen Ihrer Erkrankung 
behandelt worden? 
 Nein   Ja. Wenn ja: 
 
In welcher Klinik? Fachabteilung  Wegen Wie lange? 
   
Tage 

























Welches Verkehrsmittel haben Sie auf dem Weg zu 
Ihrer Tagesklinikbehandlung benutzt? 
Kosten der Fahrten insgesamt, falls 
bekannt 
 





 Privat Pkw 
 
 
3. Sind Sie in den letzten 6 Monaten im Krankenhaus stationär wegen Ihrer Erkrankung behandelt 
worden? 
 Nein   Ja. Wenn ja: 
 
In welchem 
Krankenhaus? Fachabteilung  Wegen Wie lange? 
   
Tage 
   
Tage 
 
4. Sind Sie seit Ihrer Rehabilitation im Krankenhaus ambulant ärztlich wegen Ihrer Erkrankung 
behandelt worden? 
 Nein   Ja. Wenn ja: 
 
In welcher Klinik? Fachabteilung  Wegen Wie lang? 
   
Tage 
   
Tage 
Welches Verkehrsmittel haben Sie auf dem Weg zu 
Ihrer ambulanten Behandlung benutzt? Kosten insgesamt, falls bekannt 
 





 Privat Pkw 
 
 
5. Haben Sie in den letzten 6 Monaten wegen Ihrer Erkrankung an einer Selbsthilfegruppe 
teilgenommen? 
 Nein   Ja: Wie oft im Monat? ______. Wie lange? ______ Monate. 
6. Haben Sie in den letzten 6 Monaten einen Notdienst aufgrund Ihrer Erkrankung in Anspruch 
genommen? 
 Nein, ich habe keinen Notdienst in Anspruch genommen 
 Ja, ich wurde im Krankenhaus in einer Notfallambulanz behandelt. Wie oft? _____ 
 Ja, ich habe einen Bereitschaftsarzt zu Hause benötigt. Wie oft? _____ 
 Ja, ich habe einen Krankenwagen nur mit Sanitätern benötigt. Wie oft? _____ 







7. Haben Sie in den letzten 6 Monaten ambulante therapeutische Leistungen wegen Ihrer 
Erkrankung in Anspruch genommen? 
 Nein   Ja. Falls ja, kreuzen Sie bitte an welche: 
 










 Psychologische Behandlung 
Mal 








Welches Verkehrsmittel haben Sie auf dem Weg zu Ihrer 
Therapie benutzt? 
Kosten der Fahrten insgesamt, 
falls bekannt 
 










8. Haben Sie in den letzten 6 Monaten eine Hilfsmittelversorgung (z. B. Gehhilfe, Rollstuhl, 
Schienen, Bandagen, Einlagen) wegen Ihrer Erkrankung in Anspruch genommen? 
 Nein   Ja. Wenn ja: 
 
Welche Hilfsmittel? Kosten insgesamt, falls bekannt 





 ja, einen Teil der Kosten 




 ja, einen Teil der Kosten 
 ja, Gesamtkosten 
 
9. Besitzen Sie einen Schwerbehindertenausweis? 
 





10. Haben Sie innerhalb der letzten 4 Wochen Medikamente eingenommen?  
Falls ja, legen Sie bitte einen Teil der Medikamentenverpackung bei, aus dem der Name des 
Medikamentes ersichtlich ist. 
 Nein   Ja. Wenn ja: 
 
Wie viele Tabletten am Tag 
Ärztlich verschriebene Medikamente 
 
Name 






   
3. 
   
4. 
   
5. 
   
Wie viele Tabletten am Tag Selbstgekaufte Medikamente (ohne Verschreibung) 
 






   
3. 
   
 
11. Sind Sie von Zuzahlungen befreit?   Nein   Ja 
 
12. Wenn Sie an Ihre Erkrankung denken: Haben Ihnen Angehörige oder Freunde/Bekannte in den 
letzten 4 Wochen geholfen? 






Was wurde gemacht? 
 Bei pflegerischen Leistungen   
 Bei Arztbesuchen/ Therapien   
 Bei der Besorgung von Medikamente   
 Hilfe im Haushalt   
 
Sonstiges:   
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13. Haben Sie in den letzten 6 Monaten einen Rentenantrag gestellt? 
 
 Nein, ich bin schon Rentner 
 Nein, ich habe keinen Antrag gestellt 
 Ja, der Antrag wurde aber noch nicht bewilligt  







14. Konnten Sie wegen Ihrer Erkrankung in den letzten 6 Monaten nicht arbeiten? 
 
 Nein   Ja. Falls ja, waren Sie: 
 
 Zustand Wie lange? 
 Krankgeschrieben mit ärztlichem Attest 
Tage 
 Krank, aber ohne ärztliches Attest Tage 
 Von der Arbeit abwesend (z. B. wegen 
Arztbesuche oder Krankengymnastik) Stunden 
 
15. Haben Sie in den letzten 6 Monaten wegen Ihrer Erkrankung an einer der folgenden beruflichen 
Maßnahmen teilgenommen? 
 Nein   Ja. Falls ja, kreuzen Sie an welche: 
 
 Maßnahme Wie lange? Wer hat die Maßnahme finanziert? 
 Umschulung 
Wochen 















Vielen Dank für Ihre Mitarbeit! 
Wenn Sie erwerbstätig sind: Bitte beantworten Sie noch Frage 14 und 15. 
 
Wenn Sie nicht erwerbstätig sind: Der Fragebogen ist hier beendet. 




Fragebogen zur Erfassung von Ressourcenverbrauch 
 
Study: Evaluation of a compensatory cognitive rehabilitation program among patients with 
brain injury 




Gesundheitsökonomische Beratungsstelle der  




Fragebogen zur Erfassung von Ressourcenverbrauch 
6 Monate nach der Rehabilitation 
 
1. Waren Sie innerhalb der letzten 4 Wochen beim Arzt (Praxis) wegen Ihrer Schädel-Hirn-
Verletzung? 
 Nein   Ja. Falls ja, kreuzen Sie bitte an bei welchem: 
 
 Fachrichtung Wie oft? 




Facharzt für : 
 
_______________________________ Mal 
Welches Verkehrsmittel haben Sie auf dem Weg zu 
Ihrer Arztbesuche benutzt? 
Kosten der Fahrten 
insgesamt, falls bekannt  
 





 Privat Pkw 
 
 
2. Haben Sie in den letzten 6 Monaten einen Notdienst aufgrund Ihrer Schädel-Hirn-Verletzung (z. 
B. epileptischer Anfall) in Anspruch genommen? 
 
 Nein, ich habe keinen Notdienst in Anspruch genommen 
 Ja, ich wurde im Krankenhaus in einer Notfallambulanz behandelt. Wie oft? _____ 
 Ja, ich habe einen Bereitschaftsarzt zu Hause benötigt. Wie oft? _____ 
 Ja, ich habe einen Krankenwagen nur mit Sanitätern benötigt. Wie oft? _____ 
 Ja, ich habe einen Krankenwagen mit Sanitätern und Notarzt benötigt. Wie oft? _____ 
 
3. Haben Sie in den letzten 6 Monaten eine Hilfsmittelversorgung (z. B. Gehhilfe, Rollstuhl, 
Schienen) wegen Ihrer Schädel-Hirn-Verletzung in Anspruch genommen? 
 Nein   Ja. Wenn ja: 
 
Welche Hilfsmittel? Kosten insgesamt, falls bekannt 





 ja, einen Teil der Kosten 




 ja, einen Teil der Kosten 























4. Haben Sie innerhalb der letzten 4 Wochen Medikamente eingenommen? Falls ja, legen Sie bitte 
einen Teil der Medikamentenverpackung bei, aus dem der Name des Medikamentes ersichtlich 
ist. 
 Nein   Ja. Wenn ja: 
 
Wie viele Tabletten am Tag 
Ärztlich verschriebene Medikamente 
Name 






   
3. 
   
4. 
   
5. 
   
Wie viele Tabletten am Tag Selbstgekaufte Medikamente (ohne Verschreibung) 
 






   
3. 
   
 
 
5. Sind Sie von Zuzahlungen befreit?   Nein   Ja 
 
 
6. Konnten Sie wegen Ihrer Schädel-Hirn-Verletzung in den letzten 6 Monaten nicht arbeiten? 
 
 Nein   Ja. Falls ja, waren Sie: 
 
 Zustand Wie lange? 
 Krankgeschrieben mit ärztlichem Attest 
Tage 
 Krank, aber ohne ärztliches Attest Tage 
 Von der Arbeit abwesend (z. B. wegen 






7. Haben Sie in den letzten 6 Monaten ambulante therapeutische Leistungen wegen Ihrer Schädel-
Hirn-Verletzung in Anspruch genommen? 
 Nein   Ja. Falls ja, kreuzen Sie bitte an welche: 
 


















Welches Verkehrsmittel haben Sie auf dem Weg zu Ihrer 
Therapie benutzt? 
Kosten der Fahrten insgesamt, 
falls bekannt 


























Gesundheitsökonomische Beratungsstelle der  




Fragebogen zur Erfassung von Ressourcenverbrauch 
12 Monate nach der Rehabilitation 
 
 
1. Waren Sie innerhalb der letzten 4 Wochen beim Arzt (Praxis) wegen Ihrer Schädel-Hirn-
Verletzung? 
 Nein   Ja. Falls ja, kreuzen Sie bitte an bei welchem: 
 
 Fachrichtung Wie oft? 




Facharzt für : 
 
_______________________________ Mal 
Welches Verkehrsmittel haben Sie auf dem Weg zu 
Ihrer Arztbesuche benutzt? 
Kosten der Fahrten 
insgesamt, falls bekannt  
 










2. Sind Sie in den letzten 12 Monaten im Krankenhaus in einer Tagesklinik wegen Ihrer Schädel-
Hirn-Verletzung behandelt worden?  Nein  Ja. Wenn ja: 
 
In welcher Klinik? Fachabteilung  Wegen Wie lange? 
   
Tage 
   
Tage 
Welches Verkehrsmittel haben Sie auf dem Weg zu 
Ihrer Tagesklinikbehandlung benutzt? 
Kosten der Fahrten insgesamt, falls 
bekannt 
 



































3. Sind Sie in den letzten 12 Monaten im Krankenhaus stationär wegen Ihrer Schädel-Hirn-
Verletzung behandelt worden?   
 
 Nein   Ja. Wenn ja: 
 
In welchem 
Krankenhaus? Fachabteilung  Wegen Wie lange? 
   
Tage 
   
Tage 
 
4. Haben Sie in den letzten 6 Monaten einen Notdienst aufgrund Ihrer Schädel-Hirn-Verletzung (z. 
B. epileptischer Anfall) in Anspruch genommen? 
 
 Nein, ich habe keinen Notdienst in Anspruch genommen 
 Ja, ich wurde im Krankenhaus in einer Notfallambulanz behandelt. Wie oft? _____ 
 Ja, ich habe einen Bereitschaftsarzt zu Hause benötigt. Wie oft? _____ 
 Ja, ich habe einen Krankenwagen nur mit Sanitätern benötigt. Wie oft? _____ 
 Ja, ich habe einen Krankenwagen mit Sanitätern und Notarzt benötigt. Wie oft? _____ 
 
5. Haben Sie innerhalb der letzten 4 Wochen Medikamente eingenommen? Falls ja, legen Sie bitte 
einen Teil der Medikamentenverpackung bei, aus dem der Name des Medikamentes ersichtlich 
ist.   Nein   Ja. Wenn ja: 
 
Wie viele Tabletten am Tag 
Ärztlich verschriebene Medikamente 
Name 






   
3. 
   
4. 
   
5. 
   
Wie viele Tabletten am Tag Selbstgekaufte Medikamente (ohne Verschreibung) 
 






   
3. 




6. Sind Sie von Zuzahlungen befreit?   Nein   Ja 
 
 
7. Haben Sie in den letzten 6 Monaten eine Hilfsmittelversorgung (z. B. Gehhilfe, Rollstuhl, 
Schienen) wegen Ihrer Schädel-Hirn-Verletzung in Anspruch genommen? 
 
 Nein   Ja. Wenn ja: 
 
Welche Hilfsmittel? Kosten insgesamt, falls bekannt 





 ja, einen Teil der Kosten 




 ja, einen Teil der Kosten 
 ja, Gesamtkosten 
 
 
8. Haben Sie in den letzten 6 Monaten ambulante therapeutische Leistungen wegen Ihrer Schädel-
Hirn-Verletzung in Anspruch genommen? 
 Nein   Ja. Falls ja, kreuzen Sie bitte an welche: 
 


















Welches Verkehrsmittel haben Sie auf dem Weg zu Ihrer 
Therapie benutzt? 
Kosten der Fahrten insgesamt, 
falls bekannt 
 
















9. Haben Sie in den letzten 12 Monaten aufgrund Ihrer Schädel-Hirn-Verletzung Umbauten bzw. 
Anpassungen in Ihrem Haus bzw. in Ihrer Wohnung ( z. B. Sitzerhöhung in der Toilette, Handlauf 
an der Wand) oder an Ihrem Arbeitsplatz vorgenommen? 
 Nein   Ja. Wenn ja: 
 

























 Ja: Wie oft im Monat? ______ Mal. Wie lange?  ______ Monate. 
 
11. Haben Sie seit Ihrer Rehabilitation wegen Ihrer Schädel-Hirn-Verletzung an einer der folgenden 
beruflichen Maßnahmen teilgenommen? 
 Nein   Ja. Falls ja, kreuzen Sie bitte an welche: 
 
 Maßnahme Wie lange? Wer hat die Maßnahme finanziert? 
 Umschulung 
Wochen 
















12. Besitzen Sie einen Schwerbehindertenausweis? 
 














13. Konnten Sie wegen Ihrer Schädel-Hirn-Verletzung in den letzten 12 Monaten nicht arbeiten?
  Nein   Ja. Falls ja, waren Sie: 
 
 Zustand Wie lange? 
 Krankgeschrieben mit ärztlichem Attest 
Tage 
 Krank, aber ohne ärztliches Attest Tage 
 Von der Arbeit abwesend (z. B. wegen 
Arztbesuche oder Krankengymnastik) Stunden 
 
14. Haben Sie seit Ihrer Rehabilitation einen Rentenantrag gestellt? 
 
 Nein, ich bin schon Rentner 
 Nein, ich habe keinen Antrag gestellt 
 Ja, der Antrag wurde aber noch nicht bewilligt  





Fragebogen zur Erfassung von Ressourcenverbrauch 
 
Study: Evaluation of a multidisciplinary prevention program against LBP: a randomized 
controlled trial in a nursing population 




Gesundheitsökonomische Beratungsstelle der  




Fragebogen zur Erfassung von Ressourcenverbrauch und Kosten  
12 Monate vor dem Präventionsprogramm 
 
Liebe Teilnehmerin, lieber Teilnehmer, 
 
Dieser Fragebogen ist Teil der Studie, an der Sie gerade teilnehmen. Alle Fragen beziehen sich auf 
Ihre Rückenbeschwerden. Bitte nehmen Sie sich ein paar Minuten Zeit und beantworten Sie die 
folgenden Fragen. Für Ihre Mitarbeit bedanken wir uns herzlich! 
 
1. Waren Sie innerhalb der letzten 12 Monaten beim Arzt (Praxis) wegen Ihrer 
Rückenbeschwerden? 
 Nein   Ja. Falls ja, kreuzen Sie bitte an bei welchem: 
 
 Fachrichtung Wie oft? 
 Hausarzt Mal 
 Orthopäde Mal 
 Internist  Mal 
 Neurologe Mal 
 Facharzt für : 
Mal 
 
2. Sind Sie in den letzten 12 Monaten im Krankenhaus stationär wegen Ihrer Rückenbeschwerden 
behandelt worden?   Nein   Ja. Wenn ja: 
 
In welchem 
Krankenhaus? Fachabteilung  Grund der Behandlung 
Wie viele 
Tage? 
   
 
   
 
 
3. Haben Sie in den letzten 12 Monaten an einer Rehabilitationsmaßnahme („Kur“) wegen Ihrer 
Rückenbeschwerden teilgenommen?  Nein   Ja. Wenn ja: 
 
In welcher Klinik? Fachabteilung  Grund der Behandlung Wie viele Tage? 
   
 
























4. Haben Sie innerhalb der letzten 12 Monaten Medikamente wegen Ihrer Rückenbeschwerden 
eingenommen?   Nein   Ja. Wenn ja: 
 
Ärztlich verschriebene Medikamente 
Medikamenten 
















































Selbstbesorgte Medikamente (ohne Verschreibung) 
Medikamenten 


















































5. Haben Sie in den letzten 12 Monaten aufgrund Ihrer Rückenbeschwerden (z. B. Hexenschuss, 
Bandscheibevorfall) einen Notdienst in Anspruch genommen? 
 
 Nein, ich habe keinen Notdienst in Anspruch genommen 
 Ja, ich wurde im Krankenhaus in einer Notfallambulanz behandelt. Wie oft? _____ 
 Ja, ich habe einen Bereitschaftsarzt zu Hause benötigt. Wie oft? _____ 
 Ja, ich habe einen Krankenwagen nur mit Sanitätern benötigt. Wie oft? _____ 
 Ja, ich habe einen Krankenwagen mit Sanitätern und Notarzt benötigt. Wie oft? _____ 
 
6. Haben Sie in den letzten 12 Monaten ambulante therapeutische Leistungen wegen Ihrer 
Rückenbeschwerden in Anspruch genommen?  
 Nein   Ja. Falls ja, kreuzen Sie bitte an welche: 
 
Art der Therapie Wie oft? 
 
Krankengymnastik (Physiotherapie) 
Therapiebezeichnung: _______________________________________ Mal 
 
Massage 
Therapiebezeichnung: _______________________________________ Mal 
 Ergotherapie 
Mal 
 Psychotherapie wegen Rückenbeschwerden 
Mal 




 Anwendungen vom Heilpraktiker 
Mal 
 Anwendung vom Chiropraktiker 
Mal 
 PMR (Progressive Muskelrelaxaktion) 
Mal 





7. Haben Sie in den letzten 12 Monaten eine Hilfsmittelversorgung (z. B. Korsett, Bandagen, 
Einlagen) wegen Ihrer Rückenbeschwerden in Anspruch genommen?  
 Nein   Ja. Wenn ja: 
 
Welche Hilfsmittel? Kosten insgesamt, falls bekannt 





 ja, einen Teil der Kosten 




 ja, einen Teil der Kosten 
 ja, Gesamtkosten 
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8. Haben Sie in den letzten 12 Monaten wegen Ihrer Rückenbeschwerden körperlichen Aktivitäten 
unternommen?   Nein   Ja. Falls ja, kreuzen Sie bitte an welche: 
 
Aktivität Wie viele Stunden in der Woche? Wie lang? 
 Gymnastikkurs 
 Monate 
 Gymnastik daheim 
 Monate 




 PMR (Progressive Muskelrelaxaktion) 
 Monate 







9. Konnten Sie wegen Ihrer Rückenbeschwerden in den letzten 12 Monaten nicht arbeiten? 
 Nein   Ja. Falls ja, waren Sie: 
 
 Zustand Wie lange? 
 Krankgeschrieben mit ärztlichem Attest 
Tage 
 Krank, aber ohne ärztliches Attest Tage 
 Von der Arbeit abwesend (z. B. wegen 
Arztbesuche oder Krankengymnastik) Stunden 
 
10. Haben Sie in den letzten 12 Monaten wegen Ihrer Rückenbeschwerden an einer der 
folgenden beruflichen Maßnahmen teilgenommen? 
 Nein   Ja. Falls ja, kreuzen Sie an welche: 
 
 
Maßnahme Wie lange? Wer hat die Maßnahme finanziert? 
 Umschulung 
Wochen 
 berufliche Fördermaßnahme 
Wochen 
 Weiterbildung (z. B. Fortbildung in 














Gesundheitsökonomische Beratungsstelle der  




Fragebogen zur Erfassung von Ressourcenverbrauch und Kosten  
3 Monate nach dem Präventionsprogramm 
 
Liebe Teilnehmerin, lieber Teilnehmer, 
 
Dieser Fragebogen ist Teil der Studie, an der Sie gerade teilnehmen. 
Alle Fragen beziehen sich auf Ihre Rückenbeschwerden und erfassen den Zeitraum von 3 
Monaten nach Ende des Präventionsprogramms.  
Bitte nehmen Sie sich ein paar Minuten Zeit und beantworten Sie die folgenden Fragen.  
Für Ihre Mitarbeit bedanken wir uns herzlich! 
 
1. Waren Sie innerhalb der letzten 3 Monaten beim Arzt (Praxis) wegen Ihrer 
Rückenbeschwerden? 
 
 Nein   Ja. Falls ja, kreuzen Sie bitte an bei welchem: 
 
 Fachrichtung Wie oft? 
 Hausarzt Mal 
 Orthopäde Mal 
 Internist  Mal 
 Neurologe Mal 
 Facharzt für : Mal 
 
2. Haben Sie seit Ende des Präventionsprogramms wegen Ihrer Rückenbeschwerden körperlichen 
Aktivitäten unternommen?   Nein   Ja. Falls ja, kreuzen Sie bitte an welche: 
 
Aktivität Wie viele Stunden in der Woche? Wie lange? 
 Gymnastikkurs 
Std. / Woche Monate 
 Gymnastik daheim 
Std. / Woche Monate 
 Schwimmen  
Std. / Woche Monate 
 Fitness-Studio 
Std. / Woche Monate 
 Autogenes Training 
Std. / Woche Monate 
 Sonstiges: 
























3. Haben Sie innerhalb der letzten 3 Monaten Medikamente wegen Ihrer Rückenbeschwerden 
eingenommen?   Nein   Ja. Wenn ja: 
 
Ärztlich verschriebene Medikamente 
Medikamenten 
















































Selbstbesorgte Medikamente (ohne Verschreibung) 
Medikamenten 






















































4. Haben Sie in den letzten 3 Monaten ambulante therapeutische Leistungen wegen Ihrer 
Rückenbeschwerden in Anspruch genommen? 
 Nein   Ja. Falls ja, kreuzen Sie bitte an welche: 
 
Art der Therapie Wie oft? 
 
Krankengymnastik (Physiotherapie) 
Therapiebezeichnung: _______________________________________ Mal 
 
Massage 
Therapiebezeichnung: _______________________________________ Mal 
 Ergotherapie 
Mal 
 Psychotherapie wegen Rückenbeschwerden 
Mal 




 Anwendungen vom Heilpraktiker 
Mal 
 Anwendung vom Chiropraktiker 
Mal 
 PMR (Progressive Muskelrelaxaktion) 
Mal 





5. Konnten Sie wegen Ihrer Rückenbeschwerden in den letzten 3 Monaten nicht arbeiten? 
 Nein   Ja. Falls ja, waren Sie: 
 
 Zustand Wie lange? 
 Krankgeschrieben mit ärztlichem Attest 
Tage 
 Krank, aber ohne ärztliches Attest Tage 
 Von der Arbeit abwesend (z. B. wegen 





Gesundheitsökonomische Beratungsstelle der  




Fragebogen zur Erfassung von Ressourcenverbrauch und Kosten  
12 Monate nach dem Präventionsprogramm 
 
Liebe Teilnehmerin, lieber Teilnehmer, 
 
Dieser Fragebogen ist Teil der Studie, an der Sie gerade teilnehmen. 
Alle Fragen beziehen sich auf Ihre Rückenbeschwerden und erfassen den Zeitraum von 12 
Monaten nach Ende des Präventionsprogramms.  
Bitte nehmen Sie sich ein paar Minuten Zeit und beantworten Sie die folgenden Fragen.  
Für Ihre Mitarbeit bedanken wir uns herzlich! 
 
6. Waren Sie innerhalb der letzten 12 Monaten beim Arzt (Praxis) wegen Ihrer 
Rückenbeschwerden? 
 Nein   Ja. Falls ja, kreuzen Sie bitte an bei welchem: 
 
 Fachrichtung Wie oft? 
 Hausarzt Mal 
 Orthopäde Mal 
 Internist  Mal 
 Neurologe Mal 
 Facharzt für : 
Mal 
 
7. Sind Sie in den letzten 12 Monaten im Krankenhaus stationär wegen Ihrer Rückenbeschwerden 
behandelt worden?   Nein   Ja. Wenn ja: 
 
In welchem 
Krankenhaus? Fachabteilung  Grund der Behandlung 
Wie viele 
Tage? 
   
 
   
 
 
8. Haben Sie in den letzten 12 Monaten an einer Rehabilitationsmaßnahme („Kur“) wegen Ihrer 
Rückenbeschwerden teilgenommen?  Nein   Ja. Wenn ja: 
 
In welcher Klinik? Fachabteilung  Grund der Behandlung Wie viele Tage? 
   
 
























9. Haben Sie innerhalb der letzten 12 Monaten Medikamente wegen Ihrer Rückenbeschwerden 
eingenommen?   Nein   Ja. Wenn ja: 
 
Ärztlich verschriebene Medikamente 
Medikamenten 
















































Selbstbesorgte Medikamente (ohne Verschreibung) 
Medikamenten 


















































10. Haben Sie in den letzten 12 Monaten aufgrund Ihrer Rückenbeschwerden (z. B. 
Hexenschuss, Bandscheibevorfall) einen Notdienst in Anspruch genommen? 
 
 Nein, ich habe keinen Notdienst in Anspruch genommen 
 Ja, ich wurde im Krankenhaus in einer Notfallambulanz behandelt. Wie oft? _____ 
 Ja, ich habe einen Bereitschaftsarzt zu Hause benötigt. Wie oft? _____ 
 Ja, ich habe einen Krankenwagen nur mit Sanitätern benötigt. Wie oft? _____ 
 Ja, ich habe einen Krankenwagen mit Sanitätern und Notarzt benötigt. Wie oft? _____ 
 
11. Haben Sie in den letzten 12 Monaten ambulante therapeutische Leistungen wegen Ihrer 
Rückenbeschwerden in Anspruch genommen?  
 Nein   Ja. Falls ja, kreuzen Sie bitte an welche: 
 
Art der Therapie Wie oft? 
 
Krankengymnastik (Physiotherapie) 
Therapiebezeichnung: _______________________________________ Mal 
 
Massage 
Therapiebezeichnung: _______________________________________ Mal 
 Ergotherapie 
Mal 
 Psychotherapie wegen Rückenbeschwerden 
Mal 




 Anwendungen vom Heilpraktiker 
Mal 
 Anwendung vom Chiropraktiker 
Mal 
 PMR (Progressive Muskelrelaxaktion) 
Mal 





12. Haben Sie in den letzten 12 Monaten eine Hilfsmittelversorgung (z. B. Korsett, Bandagen, 
Einlagen) wegen Ihrer Rückenbeschwerden in Anspruch genommen?  
 Nein   Ja. Wenn ja: 
 
Welche Hilfsmittel? Kosten insgesamt, falls bekannt 





 ja, einen Teil der Kosten 




 ja, einen Teil der Kosten 
 ja, Gesamtkosten 
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13. Haben Sie seit Ende des Präventionsprogramms wegen Ihrer Rückenbeschwerden 
körperlichen Aktivitäten unternommen?   Nein   Ja. Falls ja, kreuzen Sie 
bitte an welche: 
 
Aktivität Wie viele Stunden in der Woche? Wie lang? 
 Gymnastikkurs 
 Monate 
 Gymnastik daheim 
 Monate 




 PMR (Progressive Muskelrelaxaktion) 
 Monate 







14. Konnten Sie wegen Ihrer Rückenbeschwerden in den letzten 12 Monaten nicht arbeiten? 
 Nein   Ja. Falls ja, waren Sie: 
 
 Zustand Wie lange? 
 Krankgeschrieben mit ärztlichem Attest 
Tage 
 Krank, aber ohne ärztliches Attest Tage 
 Von der Arbeit abwesend (z. B. wegen 
Arztbesuche oder Krankengymnastik) Stunden 
 
15. Haben Sie in den letzten 12 Monaten wegen Ihrer Rückenbeschwerden an einer der 
folgenden beruflichen Maßnahmen teilgenommen? 
 Nein   Ja. Falls ja, kreuzen Sie an welche: 
 
 Maßnahme Wie lange? Wer hat die Maßnahme finanziert? 
 Umschulung 
Wochen 
 berufliche Fördermaßnahme 
Wochen 
 Weiterbildung (z. B. Fortbildung in 















Fragebogen zur Erfassung von Ressourcenverbrauch 
 
Study: Evaluation of a multimodal therapy program for fibromyalgia patients 





Gesundheitsökonomische Beratungsstelle der  




Fragebogen zur Erfassung von Ressourcenverbrauch und Kosten  
6 Monate vor der Tagesklinikbehandlung 
 
Liebe Patientin,  
 
Dieser Fragebogen ist Teil der Studie, an der Sie gerade teilnehmen.  
Alle Fragen beziehen sich auf Ihre Fibromialgie und die damit verbundenen Erkrankungen.  
Bitte nehmen Sie sich ein paar Minuten Zeit und beantworten Sie die folgenden Fragen.  
Für Ihre Mitarbeit bedanken wir uns herzlich! 
 
1. Waren Sie innerhalb der letzten 4 Wochen ambulant ärztlich wegen Ihrer Erkrankung bei: 
 
Fachrichtung Besucht? Wie oft? 
Allgemeinarzt/Praktischer Arzt  ja       nein Mal 
Orthopäde  ja       nein Mal 
Internist  ja       nein Mal 
Frauenarzt  ja       nein Mal 
Neurologe  ja       nein Mal 
Nervenarzt   ja       nein Mal 
Psychiater   ja       nein Mal 
Urologe   ja       nein Mal 
Hals-Nasen-Ohren-Arzt   ja       nein Mal 
Radiologe  ja       nein Mal 
Sonstiger Facharzt für : 
 
________________________________________ 






















2. Wurden Sie innerhalb den letzten 4 Wochen im Krankenhaus ambulant behandelt? 
 Nein   Ja. Wenn ja, 
 
In welchem Krankenhaus? Fachabteilung  Wegen 
   
   
   
 
3. Sind Sie in den letzten 6 Monaten im Krankenhaus stationär wegen Ihrer Erkrankung behandelt 
worden? 
 Nein   Ja. Wenn ja:  
 
In welchem 
Krankenhaus? Fachabteilung  Wegen 
Wie 
lang? 
   
 
   
 
   
 
 
4. Sind Sie in den letzten 6 Monaten im Krankenhaus in einer anderen Tagesklinik wegen Ihrer 
Erkrankung behandelt worden? 
 
 Nein   Ja. Wenn ja: 
 
In welchem 
Krankenhaus? Fachabteilung  Wegen 
Wie 
lang? 
   
 
   
 
   
 
 
5. Haben Sie in den letzten 6 Monaten einen Notdienst aufgrund Ihrer Erkrankung (z. B. starke 
Schmerzen) in Anspruch genommen? 
 
 Nein, ich habe keinen Notdienst in Anspruch genommen 
 Ja, ich wurde im Krankenhaus in einer Notfallambulanz behandelt. Wie oft? _____ 
 Ja, ich habe einen Bereitschaftsarzt zu Hause benötigt. Wie oft? _____ 
 Ja, ich habe einen Krankenwagen nur mit Sanitätern benötigt. Wie oft? _____ 
 Ja, ich habe einen Krankenwagen mit Sanitätern und Notarzt benötigt. Wie oft? _____ 
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6. Welche Medikamente haben Sie innerhalb der letzten Woche eingenommen?  
(Sie Können wahlweise Verpackungen oder eine Medikamentenliste beilegen) 
 
Wie viele Tabletten am Tag 






   
3. 
   
4. 
   
 
7. Welche Medikamenten haben Sie sich innerhalb der letzten Woche selber gekauft? 
 
Dosierung am Tag 






   
 
8. Sind Sie von Zuzahlungen befreit?    Nein   Ja 
 
9. Haben Sie innerhalb der letzten 4 Wochen ambulant folgende therapeutischen Leistungen 
wegen Ihrer Erkrankung in Anspruch genommen? 
 











 ja Ergotherapie  
 ja Psychologie/Psychotherapie  
 ja Anwendungen vom Heilpraktiker  





10. Haben Sie in den letzten 6 Monaten eine Hilfsmittelversorgung (z. B. Gehhilfe, Rollstuhl, 
Schienen, Bandagen, Einlagen) wegen Ihrer Erkrankung in Anspruch genommen? 
 
 Nein   Ja. Wenn ja: 
 
Welche Kosten insgesamt, falls bekannt Mußten Sie zuzahlen? 
 
  Nein   
Ja 
 
  Nein   
Ja 
 
11. Welche Fahrtkosten hatten Sie wegen Ihrer Erkrankung für Arztbesuche und Therapien und 
mit welchen Verkehrsmitteln haben Sie die Fahrten zu Arzt und Therapie unternommen? 
 
Fahrmittel Wie oft im letzten Monat? 
Höhe der Kosten, 
falls bekannt 
Taxi  nein      
 ja   
Öffentliche Verkehrsmittel  nein      
 ja   
Privat-Pkw  nein      
 ja   
Krankenwagen  nein      
 ja   
 
12. Haben Sie in den letzten 6 Monaten an einer Selbsthilfegruppe teilgenommen? 
 
 Nein   Ja. Wie oft im Monat? ______ Mal 
 
13. Haben Sie in den letzten 6 Monaten an einer beruflichen Fördermaßnahme, Weiterbildung 
oder Umschulung teilgenommen? 
 
 Nein   Ja. Wenn ja: Wie lange? __________________________ 
Wer hat sie finanziert?  Unfallversicherung 
 Rentenversicherung  
 Arbeitsamt  
 Selbst 
14. Besitzen Sie einen Schwerbehindertenausweis? 
 
 Nein   
 
 Ja mit Behinderungsgrad: _______%     Welches Merkzeichen?_____ 
 
15. Wie viele Tage in den letzten 6 Monaten konnten Sie nicht arbeiten und waren 






16. Haben Sie in den letzten 6 Monaten einen Rentenantrag gestellt? 
 
 Nein 
 Ja, aber noch nicht bewilligt  
 Ja, ich wurde berentet am ___________ 




Gesundheitsökonomische Beratungsstelle der  




Fragebogen zur Erfassung von Ressourcenverbrauch und Kosten  
6 Monate nach der Tagesklinikbehandlung 
 
Liebe Patientin,  
 
Dieser Fragebogen ist Teil der Studie, an der Sie gerade teilnehmen.  
Alle Fragen beziehen sich auf Ihre Fibromialgie und die damit verbundenen Erkrankungen. 
Bitte nehmen Sie sich ein paar Minuten Zeit und beantworten Sie die folgenden Fragen.  
Für Ihre Mitarbeit bedanken wir uns herzlich! 
 
1. Waren Sie innerhalb der letzten 4 Wochen ambulant ärztlich wegen Ihrer Erkrankung bei: 
 
Fachrichtung Besucht? Wie oft? 
Allgemeinarzt/Praktischer Arzt  ja       nein Mal 
Orthopäde  ja       nein Mal 
Internist  ja       nein Mal 
Frauenarzt  ja       nein Mal 
Neurologe  ja       nein Mal 
Nervenarzt   ja       nein Mal 
Psychiater   ja       nein Mal 
Urologe   ja       nein Mal 
Hals-Nasen-Ohren-Arzt   ja       nein Mal 
Radiologe  ja       nein Mal 


























2. Wurden Sie innerhalb den letzten 4 Wochen im Krankenhaus ambulant behandelt? 
 Nein   Ja. Wenn ja, 
In welchem Krankenhaus? Fachabteilung  Wegen 
   
   
   
 
3. Sind Sie nach Ende Ihrer Tagesklinikbehandlung in den letzten 6 Monaten im Krankenhaus 
stationär wegen Ihrer Erkrankung behandelt worden? 
 
 Nein   Ja. Wenn ja:  
In welchem 
Krankenhaus? Fachabteilung  Wegen 
Wie 
lang? 
   
 
   
 
   
 
 
4. Sind Sie nach Ende Ihrer Tagesklinikbehandlung in den letzten 6 Monaten im Krankenhaus in 
einer anderen Tagesklinik wegen Ihrer Erkrankung behandelt worden? 
 
 Nein   Ja. Wenn ja: 
In welchem 
Krankenhaus? Fachabteilung  Wegen 
Wie 
lang? 
   
 
   
 
   
 
 
5. Haben Sie in den letzten 6 Monaten einen Notdienst aufgrund Ihrer Erkrankung (z. B. starke 
Schmerzen) in Anspruch genommen? 
 
 Nein, ich habe keinen Notdienst in Anspruch genommen 
 Ja, ich wurde im Krankenhaus in einer Notfallambulanz behandelt. Wie oft? _____ 
 Ja, ich habe einen Bereitschaftsarzt zu Hause benötigt. Wie oft? _____ 
 Ja, ich habe einen Krankenwagen nur mit Sanitätern benötigt. Wie oft? _____ 




6. Welche Medikamente haben Sie innerhalb der letzten Woche eingenommen? 
(Sie Können wahlweise Verpackungen oder eine Medikamentenliste beilegen) 
 
Wie viele Tabletten am Tag 






   
3. 
   
4. 
   
 
7. Welche Medikamenten haben Sie sich innerhalb der letzten Woche selber gekauft? 
 
Dosierung am Tag 






   
 
8. Sind Sie von Zuzahlungen befreit?    Nein   Ja 
 
9. Haben Sie innerhalb der letzten 4 Wochen ambulant folgende therapeutischen Leistungen 
wegen Ihrer Erkrankung in Anspruch genommen? 
 
Art der Therapie Wie oft? 
 ja Krankengymnastik (Physiotherapie) 
Therapiebezeichnung: _____________________________________ 
 
 ja Massage 
Therapiebezeichnung: _____________________________________ 
 
 ja Ergotherapie  
 ja Psychologie/Psychotherapie  
 ja Anwendungen vom Heilpraktiker  







10. Haben Sie in den letzten 6 Monaten eine Hilfsmittelversorgung (z. B. Gehhilfe, Rollstuhl, 
Schienen, Bandagen, Einlagen) wegen Ihrer Erkrankung in Anspruch genommen? 
 
 Nein   Ja. Wenn ja: 
 
Welche Kosten insgesamt, falls bekannt Mußten Sie zuzahlen? 
 
  Nein 
 Ja 
 
  Nein 
 Ja 
 
11. Welche Fahrtkosten hatten Sie wegen Ihrer Erkrankung für Arztbesuche und Therapien und 
mit welchen Verkehrsmitteln haben Sie die Fahrten zu Arzt und Therapie unternommen? 
 
Fahrmittel 
Wie oft im letzten 
Monat? 




 ja   
Öffentliche Verkehrsmittel 
 nein 
 ja   
Privat-Pkw 
 nein 
 ja   
Krankenwagen 
 nein 
 ja   
 
12. Haben Sie in den letzten 6 Monaten an einer Selbsthilfegruppe teilgenommen? 
 
 Nein   Ja. Wie oft im Monat? ______ Mal 
 
13. Haben Sie seit Ihrer Tagesklinikbehandlung an einer beruflichen Fördermaßnahme, 
Weiterbildung oder Umschulung teilgenommen? 
 
 Nein   Ja. Wenn ja: Wie lange? __________________________ 
Wer hat sie finanziert?  Unfallversicherung 
 Rentenversicherung  
 Arbeitsamt  
 Selbst 
14. Besitzen Sie einen Schwerbehindertenausweis? 
 
 Nein 




15. Wie viele Tage in den letzten 6 Monaten konnten Sie nicht arbeiten und waren 




16. Haben Sie seit Ihrer Tagesklinikbehandlung einen Rentenantrag gestellt? 
 
 Nein 
 Ja, aber noch nicht bewilligt  
 Ja, ich wurde berentet am ___________ Art der Rente?__________________________ 
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